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AWARENESS AND UTILIZATION OF THE OHIO AUTOMATED RX REPORTING 
 
SYSTEM BY PHYSICIAN ASSISTANTS 
 
 
Abstract 
 
 
 
Chronic pain has become a public health epidemic. As pain complaints increase, so does 
the potential for drug abuse/misuse. Prescription drug monitoring programs (PDMPs) are active 
in 49 of the 50 states to assist providers in recognizing drug abuse/misuse. There is no clear 
standardization of who utilizes the PDMP and how. Little is still known about the ways PDMP 
results are incorporated into clinical decision making, what barriers exist, and how providers 
may or may not alter their prescribing plans based on the results. Laws surrounding prescribing 
practices and use of the Ohio Automated Rx Reporting System (OARRS) are constantly updated. 
Existing literature was reviewed regarding state PDMPs, OARRS, Ohio Revised Code, 
limitations of PDMPs, and physician assistants (PAs) role in using the OARRS. Current 
literature shows underutilization and lack of awareness of the OARRS by PAs. Quantitative data 
was collected using a twenty-six question electronic survey distributed to PAs actively licensed 
to practice in the State of Ohio as of February 25, 2014 (n= 2563) with a rate of return of 15.6%. 
Results showed 73.80% of PAs indicated that they were currently enrolled in OARRS and 
26.20% indicated they were not enrolled. Of the PAs enrolled in OARRS, 71.87% responded that 
they do utilize the OARRS and of those enrolled, 74.04% report an average use of at least once 
per week. Routines for enrolling, accessing, and responding to OARRS results vary widely. As 
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controlled substance prescribing and use of OARRS increases, it is important to understand what 
approaches are most effective for identifying and addressing enrollment and utilization of the 
OARRS. Future trends for OARRS education on increasing enrollment and utilization of 
OARRS are described. 
 
 Keywords: OARRS, Prescription drug monitoring program, Physician assistant 
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CHAPTER 1 
 
Physician assistants (PAs) with prescriptive privileges allow for a cost effective and 
efficient bridge of the medical care gap. PAs provide increased access to desperately needed 
medical care (Cipher, Hooker, & Guerra, 2006). Hooker, Cawley and Everett (2011) agree that 
PAs have been essential during times of physician shortages. The number of board certified and 
licensed PAs continues to grow each year (Hooker et al., 2011; NP/PA prescribing stats, 2006; 
and Ross, Parle, Begg, & Kuhns, 2012). As the PA profession expands so does the need to write 
prescriptions for scheduled medications. The ability to prescribe scheduled medications is 
imperative to best practice medicine. Best practice medicine includes prevention, identification, 
and treatment of illnesses.  
As the need and ability for PAs to write prescriptions increases, so does the need to do so 
safely and responsibly. Rules, regulations and laws regarding a PA’s prescribing ability are still 
in their infancy and vary widely by state and institution. White and Davis (1999) found that 
“very early in the PA profession it became apparent to supervising physicians that their practice 
could be more efficient if they were allowed to delegate to PAs the prescription of medications” 
(p. 958). PAs have been prescribing medications since the 1980s when legislation was passed 
that allowed prescriptive privileges for PAs in several states (Physician Assistant Historical 
Society, 2013). According to the Drug Enforcement Administration (2013) and the American 
Academy of Physician Assistants (2010), currently 48 of the 50 states and the District of 
Columbia allow PAs the privilege to prescribe scheduled medications. PAs are often called upon 
to treat patients who have pain and require scheduled medications including opioid analgesics. 
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“Approximately 75 million people in the United States suffer from severe pain, which is the most 
common presenting complaint of patients seeking medical assistance” (Brushwood, 2003, p. 41).  
The ability to prescribe scheduled medications carries with it a duty to prescribe safely and 
responsibly.  
Pain can be treated in different ways. Pain can be treated non-pharmacologically with 
interventions such as anesthesia assistance, behavioral counseling, nerve stimulation, physical 
therapy, acupuncture, or massage. Pain can also be treated with medications such as non-
steroidal anti-inflammatory medications, anti-depressants, or opioid analgesics. When 
medications become the treatment of choice for pain (regardless of the origin of the pain) a 
balance must be achieved between safe and effective pain management and substance abuse.  
In 2006 the State of Ohio passed Senate Bill 154 giving physician assistants the right to 
prescribe schedule III-V medications (Bricker & Eckler LLP, 2006; S.B. 154, 2006). 
“Supervised prescribing (by PAs), as regulated by the state and by the physician supervisor, can 
improve patient access to comprehensive care and provide for increased efficiency and cost 
effectiveness” (Younger, P. A., & Aspen Health Law Center, 1997, p. 100). Some scheduled 
medications required prescriptions written by an attending physician with limited availability 
thus delaying relief for severe pain. In March 2013 House Bill 284 passed giving Ohio PAs 
prescriptive privileges of schedule II medications. 
As an added security resource, the Ohio Automated Rx Reporting System (OARRS) 
program was established in 2006. The OARRS is a state-wide prescription drug monitoring 
program. OARRS is available, via registration through a secure website, to all prescribers, law 
enforcement officers, and pharmacists. With the addition of Schedule II medications to PAs’ 
prescribing rights many Ohio employers found it necessary to establish or revise existing policy 
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for PA prescribing. During the policy analysis at one Ohio medical center, concerns about the 
safety of prescribing scheduled medications were identified.  
The purpose of the OARRS program is to “improve patient care and identify drug 
seeking behavior” (Feldman, Skeel-Williams, Knox, & Coates, 2012, p. 909) by tracking every 
prescription written for scheduled (II-V) medications. OARRS is designed to decrease abuse, 
misuse, “doctor shopping” (obtaining controlled substances from multiple health care providers 
without the prescribers’ knowledge of the other prescriptions) and polypharmacy, which is the 
use of multiple medications concurrently (Blumenschein et al. 2010; Feldman et al., 2011; Ohio 
Academy of Family Physicians, 2012). 
Multiple evaluations of state prescription monitoring programs have been undertaken in 
several medical fields but have not resulted in the development of a standard protocol for 
awareness and utilization of state prescription monitoring programs. Analysis of awareness and 
utilization of state prescription monitoring programs has been explored in fields including 
emergency medicine, pharmacy, pain management, psychology, and physician utilization 
(Baehren et al., 2010; Barrett & Watson, 2005; Clark, 1991; Feldman et al., 2012; Gilson & 
Joranson, 2001; Joranson et al., 2002; Katz et al., 2008; Todd, 2010; Ulbrich, Dula, Green, 
Porter, & Bennett, 2010; Wang & Christo, 2009). To date, the awareness and utilization of the 
OARRS by PAs has not been evaluated and thus it is unclear how effectively PAs access this 
established system. Information on awareness and utilization of state prescription monitoring 
programs by PAs may identify an influence on the prescribing of controlled substances. 
Information collected could be used to help shape future policy regarding PAs’ prescriptive 
privileges, education on PA prescribing in Ohio, and allow for safer and more effective 
healthcare. Therefore, further research is needed to examine the awareness and utilization of the 
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Ohio Automated Rx Reporting System by PAs. 
Purpose of the Study 
 The purpose of this study is to examine the awareness and utilization of the Ohio 
Automated Rx Reporting System by physician assistants.  
Statement of the Problem 
 Physician assistants do not adequately utilize the Ohio Automated Rx Reporting System. 
There is an overarching problem with prescription drug monitoring programs in that there is a 
lack of unification. There is not one governing body; many but not all states have a prescription 
drug monitoring program; there is no standardization of what information is collected, by whom, 
or who may access it; there is no unified system of communication between the programs in each 
state. However this larger problem is outside the scope of this study. The proposed study will 
focus on specific population and specific state monitoring program. The results from this study 
could be used to create local (hospital wide) and state policies regarding access and utilization of 
the OARRS program.  
Hypotheses 
The following null hypotheses were based on the selected review of literature and the 
intuition of the researcher: 
1. Physician assistants actively licensed to practice in the State of Ohio are 
unaware of the OARRS. 
2. Physician assistants actively licensed to practice in the State of Ohio do not 
utilize the OARRS.  
3. No factors are predictive of awareness of OARRS by physician assistants 
actively licensed to practice in the State of Ohio. 
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4. No factors are predictive of utilization of OARRS by Physician assistants 
actively licensed to practice in the State of Ohio. 
5. Physician assistants actively licensed to practice in the State of Ohio do not 
alter their prescribing plans as a result of utilization of OARRS. 
Definition of Terms 
 
For the purpose of this study, the following terms are defined.  
Awareness: Knowing that something (such as a situation, condition, or problem) exists 
(awareness, 2013). 
Continuing medical education (CME): Includes but is not limited to: graduate education, 
education for health professionals that follows completion of formal post-medical school 
specialty training. Formats include but are not limited to: lectures, seminars, refresher 
courses, workshops, audio- and video-recordings, professional organizations, hospitals 
(continuing medical education, 2002) 
Controlled substance: any drug defined in the five categories of the federal Controlled Substance 
Act of 1970. The categories, or schedules, cover opium and its derivatives, hallucinogens, 
depressants, and stimulants. Schedule I drugs have a high abuse potential and no 
approved medical uses. Drugs in Schedules II to V all have approved medical indications 
with decreasing abuse and dependence liabilities as the schedule number increases 
(controlled substance, 2009). 
Doctor shopping: Obtaining controlled substances from multiple health care providers without 
the prescribers’ knowledge of the other prescriptions (Blumenschein, et al., 2010). 
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Drug abuse/misuse: The use of a controlled substance in a maladaptive pattern resulting in 
significant impairment or distress, such as failure to fulfill social or occupational 
obligations or recurrent use in situations in which it is physically dangerous to do so or 
which end in legal problems. Abuse also encompasses inappropriate use of medications 
other than the explicit prescriber’s instructions (substance abuse, 2003). 
Drug diversion: The channeling of controlled substances to another person(s) or for any use 
other than prescribed by the provider. This can include: theft, forging, tampering, 
counterfeiting, and illegal sales (Kasprak, J., 2003). 
Drug Enforcement Administration (DEA): A United States Federal law enforcement agency 
under the Department of Justice tasked with monitoring, controlling and preventing 
illegal or inappropriate drug use (Drug Enforcement Agency; Office of Diversion 
Control, 2013).  
Medical provider: Doctor (M.D. or D.O.), dentist, nurse practitioner, physician assistant, or any 
other healthcare provider who might prescribe medications. (Blumenschein et al., 2010). 
OARRS: Ohio Automated Rx (Prescription) Reporting System. 
Opioid analgesic: Medication that binds with the opioid receptors in the central nervous system 
to block the perception of pain or affect the emotional response to pain (Opioid 
Analgesic, 2007). 
Physician assistant: A graduate of an accredited educational program and is nationally certified 
and state-licensed to practice medicine with the supervision of a physician. PAs perform 
physical examinations, diagnose and treat illnesses, order and interpret lab tests, perform 
procedures, assist in surgery, provide patient education and counseling, and make rounds  
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 in hospitals and nursing homes. All 50 states and the District of Columbia allow PAs to 
practice and prescribe medications (American Academy of Physician Assistants, 2013). 
Polypharmacy:  The use of multiple medications concurrently (Blumenschein et al., 2010). 
Prescribing privileges: A legal privilege that must be applied for by the physician assistants in 
their respective state that enables them to prescribe drugs and other medicines required 
for the treatment of medical conditions (Brian, n.d.).  
Prescription drug monitoring program: According to the National Alliance for Model State Drug 
Laws (NAMSDL, 2013), a PDMP is a statewide electronic database that collects 
designated data on substances dispensed in the state. The data from the database is 
disseminated to individuals who are authorized under state law to receive the information 
for purposes of their profession. 
Scheduled medication: Substances are placed in their respective schedules based on whether they 
have a currently accepted medical use in treatment in the United States, their relative 
abuse potential, and the likelihood of causing dependence when abused. See Table 1. 
(Drug Enforcement Agency; Office of Diversion Control, 2013).  
Supervising physician: An allopathic or osteopathic physician (M.D. or D.O.) licensed to practice 
in the state, which accepts responsibility for the supervision of services provided by a 
physician assistant. Direction of the medical practice of the physician assistant is 
provided and assured by a supervising physician, but this does not necessarily require the 
physical presence of a supervising physician at the place where services are rendered 
(American Academy of Physician Assistants, 2013). 
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Treatment plan: The intended sequence of procedures for the treatment of a patient (treatment 
plan, 2008). 
Utilization: To make use of (Utilization, 2013). 
Limitations of the Study 
1) The study is limited to the physician assistants actively licensed to practice in the 
State of Ohio. Therefore, findings from this study cannot be generalized to all 
physician assistants or physician assistants in other states.  
2) The study is limited to physician assistants. Therefore this study does not represent all 
medical providers in the State of Ohio. 
3) The completion of the survey is voluntary. Therefore some physician assistants may 
choose not to complete the questionnaire, thus, limiting sample size. 
4) The responses are self-reported.  
Assumptions   
The following were the basic assumptions of the design: 
1. The questionnaire respondents’ interpretation of the questions is accurate.  
2. The questionnaire respondents answer in an honest and thoughtful manner.  
3. An existing research tool developed by Ulbrich et al. (2010) is used with permission and 
adapted for physician assistants.  
4. The questionnaire was previously tested for validity by Ulbrich et al. (2010).  
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CHAPTER 2 
LITERATURE REVIEW 
The purpose of the chapter is to present a selected review of literature 
related to the objectives of this study. The information provided is discussed employing the best 
practice conceptual framework. The first section provides an outline of the best practice 
conceptual framework as it pertains to the awareness and utilization of the Ohio Automated Rx 
Reporting System by PAs. The second section of the review of literature discusses the history of 
prescription drug monitoring programs. Identified negatives and limitations of prescription drug 
monitoring programs are discussed in the third section. The fourth section presents information 
about the Ohio Automated Rx Reporting System. The Ohio revised code is discussed in the fifth 
section. The use of prescription drug monitoring program utilization in selected fields is 
discussed in the sixth section. The seventh section discusses the PA’s role in prescription drug 
monitoring programs. In the eighth section, PA pharmacologic education is discussed. The 
chapter concludes with a summary of the selected review of literature. 
Conceptual Framework 
 The conceptual framework used to examine the awareness and utilization of the Ohio 
Automated Rx Reporting System by PAs is Solberg’s (2007) improving medical practice. 
Improving medical practice is a framework that incorporates the vision for the PA profession; 
“PAs transforming health through patient-centered, team-based medical practice – with its 
hallmark of patient-centered, team-based care—as a driving force for significant improvement” 
(American Academy of Physician Assistants, 2013, p. 7) Through this framework the 
investigator  
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attempts to quantify the awareness and utilization of the Ohio Automated Rx Reporting System 
by PAs and how it could relate to future policies and optimal patient care.  
 The issue of appropriate use of opioids in the treatment of pain is complex and 
controversial. This debate is often highlighted in improving medical practice discussions. 
Feinberg (2011) relates that: 
On one side there is the ever increasing problem of deaths and dysfunction from the 
inappropriate use of opioids, and on the other side are the needs of patients for adequate 
pain control to facilitate comfort, activity and function. For the provider and patient, 
achieving a balance across the continuum of outcomes from pain relief, side effects, 
addiction, abuse, diversion and potential death, remains problematic. (p. 1) 
In response to the increasing morbidity and mortality associated with the increasing use 
of opioids, the Centers for Disease Control and Prevention (2010) has released several 
recommendations for health care providers for improving medical practice guidelines. The 
Center for Disease Control and Prevention (2010) recommendations include: 
The belief that opioid medications for pain should only take place after a determination 
has been made that alternative therapies have not provided adequate pain relief. 
Additionally, the lowest effective dose of opioids should be used. Behavioral screening, 
patient agreements, and random urine testing should be strongly considered in patients 
with pain, who have been treated with opioids for more than six weeks. (p. 4) 
The improving medical practice framework dictates that “opioids (despite their potential 
for problems) have a place in the practitioner’s treatment armamentarium when other methods 
have failed and when the use of opioids results in less pain, more function and manageable side-
effects” (Feinberg, 2011, p. 3). Providers must examine opioid prescribing with a risk vs. benefit 
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lens. If other non-opioid treatment methods fail and there is clinical indication for the use of 
opioids, the provider may decide opioid therapy is appropriate. 
History of Prescription Drug Monitoring Programs 
Brushwood (2003) indicates that despite the availability of safe and effective pain 
treatment options, many patients are either over or under treated. Every year thousands of visits 
are made to medical offices, emergency rooms, and urgent care facilities for pain related 
complaints. PAs are used to increase access to medical services. Due to increased availability, a 
patient often sees a PA for his/her medical care. As PAs are seeing an increased number of 
patients, and many of those patients with pain related complaints, the potential for writing 
prescriptions for opioid medications increases. There is a need to utilize available safety 
mechanisms and resources to prevent drug diversion and abuse.  
There is no standard or measurement available for medical providers to determine if a 
patient’s pain is legitimate or falsified. Medical providers rely on the patient’s history, physical 
exam, and diagnostic tests to evaluate the need for opioid analgesics to treat pain. In order to 
collect evidence on the problem of inappropriate prescribing and dispensing of controlled 
substance medications and to facilitate a resolution to the problem, states began using 
prescription drug monitoring programs (Brushwood, 2003; Fishman, Papazian, Gonzalez, 
Riches, & Gilson, 2004; GAO-04-524T, 2004; Wilsey et al., 2011).  
As medications for the management of pain have advanced over centuries, laws designed 
to regulate access to such medications also developed. “Since the early 1930s, state regulatory, 
administrative, and law enforcement agencies have seen the need for and have worked to 
establish systems to track and monitor the prescribing and dispensing of particular prescription 
drugs” (Blumenschein et al., 2010). California was the first state to establish a prescription drug 
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monitoring program in 1939. Over the years, more and more states followed California in 
establishing prescription drug monitoring programs (Fishman et al., 2004). According to the 
Alliance of States with Prescription Monitoring Programs (2001) and the National Alliance for 
Model State Drug Laws (2014) 49 states (all but Missouri) and the District of Columbia have 
prescription drug monitoring programs. The Alliance of States with Prescription Monitoring 
Programs was formed in 1990 to facilitate “the exchange of information and ideas among state 
and federal agencies on prescription monitoring programs” (Alliance of States with Prescription 
Monitoring Programs, n.d., 1).  
Attempts to monitor prescription drug use and diversion have evolved over time. Early 
forms of prescription drug monitoring programs used triplicate or carbon copy prescriptions. 
With advances in the technology during the 1990’s, some states began using computers to 
collect, track, and transmit monitoring information (Fishman et al. 2004; Todd, 2010). Another 
factor leading to the success and growth of state prescription drug monitoring programs was the 
Harold Rogers Prescription Drug Monitoring Program which was funded by the federal 
government and provided supporting funds to state prescription drug monitoring programs 
(Bureau of Justice Assistance, 2007; Fishman et al., 2004; Harold Rogers prescription drug 
monitoring program, 2013; Paulozzi, Kilbourne, & Desai, 2011; Todd, 2010).  
An additional attempt by the government to support state prescription drug monitoring 
programs was made in 2005. In August of 2005, President George W. Bush signed the National 
All Schedules Prescription Electronic Reporting (NASPER) Act into law (Manchikanti, 
Whitfield, & Pallone, 2005; Paulozzi et al., 2011). This act provided additional federal funding 
to state prescription drug monitoring programs. However, it was more than four years after the  
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passing of the legislation before any funding became available and the available funds have been 
limited (Todd, 2010).  
The federal government also attempted to increase regulations regarding the 
manufacturing and distribution of medications. The Controlled Substance Act of 1970 allowed 
the Drug Enforcement Administration to oversee the manufacturing and distribution of legal 
narcotic medications (Catholic University of America, 2009; Fishman et al., 2004; GAO-02-634, 
2002). The Drug Enforcement Administration classifies medications into five distinct categories 
or schedules depending upon the drug’s acceptable medical use and the drug’s potential for 
abuse or dependency (See Appendix A). “Abuse rate is a determinate factor in the scheduling of 
the drug” (DEA 2013). For example, Schedule I drugs are considered the “most dangerous” class 
of drugs with a “high potential for abuse” and potentially severe psychological and/or physical 
dependence. Schedule I medications have very limited medical use. As the drug schedule 
changes-- Schedule II, Schedule III, etc., so does the abuse potential-- Schedule V drugs 
represents the least potential for abuse (Sharp, 1991; Curtis et al., 2006). Because of the potential 
for abuse, opioid analgesics are regulated under federal narcotics and controlled substances laws 
(Joranson et al., 2000). According to Drug Enforcement Agency Office of Diversion Control 
(2013), 21 oral opioid analgesics are categorized at Schedule II.  
State specifications vary widely but information collected and transmitted by the state 
drug monitoring programs often include but are not limited to patient name, date of birth, 
prescriber’s name, medication, amount, and directions. (GAO-04-524T, 2004; GAO-02-634, 
2002, Kasprak, 2003; Paulozzi et al., 2011; Wilsey et al., 2011). 
Although there is significant heterogeneity regarding the specifics of how the prescription 
drug information is monitored, “states have found that prescription drug monitoring programs 
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are among the most effective tools available to identify and prevent drug diversion at the 
prescriber, pharmacy, and patient levels” (Alliance of states with prescription monitoring 
programs, 1999, 3; Woodworth, 2013). Benefits of prescription drug monitoring programs 
identified by Wang and Christo (2009), Curtis et al. (2006), and the United States General 
Accounting Office (GAO-02-634, 2002) include reduced time and effort for law enforcement 
agencies to investigate diversion and states with prescription drug monitoring programs have 
reduced the supply of controlled substances.  
Limitations of Prescription Drug Monitoring Programs 
Many medical providers and law enforcement agents will agree that drug monitoring 
programs are well intended and can be effective at curbing diversion and abuse; unintended 
consequences can limit the utility of aforementioned programs. “Despite great efforts and good 
intentions, PDMPs are considered by many healthcare providers to have a collateral of negative 
impact on other areas of legitimate medical care” (Fishman et al., 2004, p. 311). One major 
criticism of prescription drug monitoring programs is the lack of consistency in what information 
is collected, by whom, how often, and what is done with the results (Barrett and Watson, 2003; 
Blumenschein et al., 2010; Brushwood, 2003; Simeone, Holland, & Simeone Associates Inc., 
2006; Todd, 2010; U.S. Drug Enforcement Administration, 2011; Wang & Christo, 2009). 
Manchikanti et al. (2005) identified another important problem with PDMPs was the lack of 
communication between state programs.  
Limitations of electronic prescription drug monitoring programs. The two biggest 
limitations identified were cost (to the patient or the medical practice) and limited technology. 
Manchikanti et al. (2005) noted that not all states and medical facilities provide internet access to 
PDMP data. Rural health care facilities may also have limited financial and technologic access to 
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PDMP data. Electronic PDMPs carry a continuous cost of technology update (GAO-02-634, 
2002) and may be seen as an additional burden to medical practices. 
A PA can prescribe up to seven days of a Schedule II medication without the patient 
seeing the supervising physician. If your supervising physician has seen the patient 
before, and the patient is seeking a refill, you may prescribe any amount, but common 
sense would indicate no more than 30 days. (Ohio Association of Physician Assistants, 
2013, PA Formulary section, para. 14) 
It is common that state laws limit the amount of scheduled medications that can be prescribed at 
one time (typically a 30 day supply) and that increases the number of doctor visits for patients, 
thus increasing costs.  
Effects on patient care and access to opioid medications. The influence of drug 
monitoring programs can have far reaching implications not only for medical providers but also 
for their patients. Brushwood (2003), Fishman et al (2004), GAO-02-634 (2002) and Woodworth 
(2013) agree that patients fear having their information tracked and stored and the possibility for 
confidentiality breach may lead to an unfair label of “drug seeking or dependency.”  
Blumenschein et al. (2010), Fishman et al. (2004), and Manchikanti et al. (2005) found that 
PDMPs had adverse effects on provider prescribing that included inappropriate substitution of 
nonregulated medications and a decrease in number of prescriptions written. Clark (1991) also 
found that providers showed a reduced inclination to provide narcotic prescriptions for chronic 
or acute pain.  
Impact on perception of regulations and practice modification. According to Fishman 
et al. (2004) and Clark (1991) physicians are reluctant to use PDMPs due to fear of being “red 
flagged” as an over prescriber. Barrett and Watson (2005), Gilson and Joranson (2001), 
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Manchikanti et al. (2005), and Wang and Christo (2009) determined some prescribers felt that 
utilization of prescription drug monitoring programs would place scrutiny on their practice with 
potential ill effects of investigation, litigation, or reprimand. GAO-02-634 (2002) and 
Woodworth (2013) found that physicians were concerned about having their prescribing 
decisions and patterns tracked and being investigated without sufficient cause. Due to this fear of 
persecution physicians may be hesitant to prescribe certain scheduled medications or may even 
inappropriately substitute medications. To combat the fears of harassment of providers, some 
states have added statues of use for the PDMPs that ensure only authorized users access the 
information and that the information is used for intended purposed only (GAO-02-634, 2002). 
Another identified criticism of using OARRS is the burden of running the report (Woodworth, 
2013). This specific argument has been counteracted by enactment of Ohio H.B. 93 that allows 
medical support staff the ability to run an OARRS report (Ohio Revised Code 4729.80 (A)(5) 
H.B. 93). 
Fass and Hardigan (2011) surveyed pharmacists in Florida and results showed that a 
majority of the pharmacists felt that results from a PDMP report would not discourage them from 
dispensing controlled substances and would not invade patient privacy. 
Inconsistency of information gathered and utilization. Significant heterogeneity exists 
between states regarding what information is gathered and how it is utilized. Programs vary from 
state to state in what information is collected, what drugs are monitored, how information is 
collected, who has access to the information, and who monitors the program (Barrett & Watson, 
2003; Blumenschein et al., 2010; Brushwood, 2003; GAO-02-634, 2002; Simeone et al., 2006; 
Todd, 2010; U.S. Drug Enforcement Administration, 2011; Wang & Christo, 2009). States vary 
in their use of electronic versus paper prescription monitoring. Comprehensive coverage of all 
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drug schedules offers the most effective monitoring program (GAO-02-634, 2002). Twenty-four 
states have mandatory PDMP access requirements that necessitate a prescriber must run a system 
query on the patient prior to prescribing controlled medications (National Alliance for Model 
State Drug Laws, 2014). 
Ohio Automated Rx Reporting System 
Following success of prescription drug monitoring programs in multiple states as well as 
the technology boom in healthcare in the 1990s, the Ohio Automated Rx Reporting System was 
established in 2006. The OARRS is operated by the Ohio State Board of Pharmacy. Data are 
collected on prescriptions for medications scheduled II-V. The information collected is available 
to pharmacists, prescribers registered with OARRS, and law enforcement (Foxhall, 2010; 
Woodworth, 2013). OARRS reports contain patient information including patient name, date of 
birth, previous controlled prescriptions (includes prescriber, substance, amount, and date 
dispensed), pharmacies where the prescriptions were filled and all addresses used by the patient. 
Data reported by Alliance of States with Prescription Monitoring Programs (n.d.) showed that in 
2008 21,000,000 prescriptions were recorded by the OARRS and patient history was accessed 
353,500 times.  
The OARRS has developed a set of guidelines (Rule 4731-11-11) that outlines when to 
seek access to OARRS prior to prescribing or personally supplying a controlled substance (State 
Medical Board of Ohio, 2011). For an OARRS report to meet ethical standards, the provider 
running the report must be currently treating the patient (Ohio Academy of Family Physicians, 
2012). The guidelines suggest accessing and running an OARRS report: (a) if a patient is 
exhibiting signs of drug abuse or diversion; (b) when you have a reason to believe the scheduled 
medication treatment will continue for twelve weeks or more; (c) and at least once a year 
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thereafter for patients receiving scheduled medications (Ohio Academy of Family Physicians, 
2012; Ohio State Medical Association, 2013; State Medical Board of Ohio, 2011). The OARRS 
guidelines outline when a report must be run and when a report should be run.  
The Ohio Academy of Family Physicians (2012), Ohio State Medical Association (2013), 
and State Medical Board of Ohio (2011) agree that running an OARRS report is required by a 
medical provider when: (a) a drug screen result is inconsistent with the treatment plan (i.e., illicit 
drugs or medications not prescribed are detected in the urine toxicology screen); (b) a patient 
refuses to participate in a drug screen; (c) forging or prescription altering occurs; (d) the patient 
is suspected of selling prescription drugs; (e) the patient is suspected of stealing or borrowing 
prescription drugs; (f) the patient is suspected of receiving drugs from multiple prescribers; (g) 
the patient has been arrested; (h) the patient is suspected of drug diversion; (i) or having a family 
member, friend, law enforcement officer, or health care professional express concern related to 
the patient’s use of illegal or reported drugs.  
The Ohio Academy of Family Physicians (2012), Ohio State Medical Association (2013), 
and State Medical Board of Ohio (2011) follow OARRS guidelines and suggest running a report 
by a medical provider when: (a) a patient has a known history of chemical abuse or dependency; 
(b) a patient frequently requests early refills of scheduled medications; (c) a patient appears 
impaired or overly sedated during an office visit or exam; (d) a patient frequently loses 
prescriptions; (e) a patient requests drugs by specific name, street name, color; (f) or a patient 
shows recurring emergency department visits to obtain reported drugs. 
OAARS reports are intended to assist providers in improving prescription medication 
management for their patients and to be used as a screening tool to prevent abuse, misuse and 
diversion of controlled substances (The Columbus Dispatch, 2010; Feldman et al., 2011; GAO-
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04-524T, 2004; Ohio Academy of Family Physicians, 2012). Although there is a general 
consensus among medical providers that the best practice model includes standardization of 
medical protocols, the fact that the OARRS is underutilized and occasionally viewed as an 
elective tool versus a mandatory standard protocol is concerning.  
Ohio Revised Code 
 The Ohio Revised Code is a compilation of statues that is the source for state regulations 
for medical providers and prescribers in the State of Ohio. Bills, statutes and policies are 
constantly being revised and amended. Most recently, on September 16, 2014, Ohio House Bill 
341 was passed. Ohio Revised Code Sec 4730.53. (A)- Sec. 4731.055. (E) of House Bill 341 
(2014) states that a prescriber of controlled substances must request and document the results of 
an OARRS report prior to prescribing any medications. The report must include the last 12 
months. If the provider works in a county that borders another state, a report must be run for the 
bordering state if a drug database is available in that state. If prescribing is to continue after 
ninety days, then an additional OARRS report must be run and documented at the ninety day 
interval.  
 There are also some exceptions stated in the Ohio Revised Code Sec 4730.53. (A)- Sec. 
4731.055. (E) of House Bill 341 (2014): an OARRS report is not required if there is no report 
available, the medication is prescribed for less than a seven day period, if the medication is 
furnished for cancer treatment, for hospice care, in a nursing home, in a hospital, or for acute 
pain treatment after surgery/delivery.  
 While the above statutes and laws are helpful in providing suggestions and parameters, 
there are always limitations and margins of error that are found. There is no specific timeline set  
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for controlled substances that are prescribed after surgery. The term “acute” is not defined in a 
timeline.  
Prescription Drug Monitoring Program Utilization 
“To date little research has examined the efficacy and safety of prescription drug 
monitoring programs in clinical practice” (Todd, 2010, p. 24). The limited examination of 
prescription drug monitoring program utilization has focused on fields that have a high 
population of patients who complain of pain and might require opioid analgesics including 
emergency medicine, pain management, pharmacy, and psychology.  
Patients with painful conditions often seek care at emergency rooms as a first line of 
treatment for their pain, possibly due to late hours, frequently changing staff (shift changes of 
nurses and physicians create a window for drug diversion), or a sense that the pain requires 
urgent attention. Baehren et al. (2010) examined the influence of a state prescription drug 
monitoring program results (Ohio Automated Rx Reporting System OARRS) on clinical 
management of patients complaining of pain in the emergency department. Baehren and 
colleagues found that emergency room physicians reviewing OARRS data prior to prescribing 
medications resulted in altered prescribing plans for 41% of cases, with plans for less opioid 
medications in 61% and more opioid medications in 39% of cases. Todd (2010) states that the 
data found by Baehren et al. do not reveal why the OARRS data changed the prescribing 
decisions. Baehren et al. and Todd agree that awareness and utilization of state prescription drug 
monitoring programs are useful tools for emergency medicine providers.  
“Because pain is subjectively defined, it is difficult to diagnose and treat” (Wang & 
Christo, 2009, p. 508). For this reason, providers in the pain management field have been using 
state prescription drug monitoring programs for decades (Gilson & Joranson, 2001; Joranson et 
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al., 2002; Katz et al., 2008; Manchikanti et al., 2005; Wang & Christo, 2009). Wang and Christo 
(2009) found that while states with prescription monitoring programs had lower incidences of 
abuse, misuse and diversion, neighboring states without prescription drug monitoring programs 
had increased incidences of abuse, misuse and diversion. Feldman et al. (2012) revealed that 
although states with prescription drug monitoring programs reduced the number of prescriptions 
for controlled substances being written, there was no evidence this was in a positive manner (i.e., 
preventing diversion versus inadequate pain management). These mixed results of study of 
prescription drug monitoring programs in the field of pain management warrant additional 
investigation into balancing adequate pain management with reduction in abuse, misuse and 
diversion.  
The research done by Ulbrich et al. (2010) examined factors influencing the enrollment 
of a group of pharmacists in Ohio in the OARRS program. Results of the study showed that the 
pharmacists that were enrolled in OARRS did so to decrease misuse, abuse and diversion and 
those pharmacists who were not enrolled cited a significant time burden to access the OARRS. 
Ulbrich  and colleagues used his research results to reform and revise continuing education 
information for pharmacists about PDMPs.  
The work done by Feldman et al. (2012) was designed to determine if attending physician 
behavior influenced the behavior of resident physicians. Feldman and colleagues surveyed 
attending and resident physicians at one hospital in the State of Ohio for awareness and 
utilization of the OARRS and found that 96% of attending physicians and 81% of resident 
physicians had awareness of the state prescription monitoring program. Of those with awareness, 
79% of attending and only 51% of residents reported utilizing the OARRS.  
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According to Feldman et al. (2012) the primary reason cited for utilizing the OARRS was 
concern for medication abuse and that information from the OARRS influenced prescribing 
habits by decreasing the quantity of medication given, changing the medication given or 
increasing the amount given.  
Feldman et al. (2012) found that in relation to physician and resident prescribing trends, 
68% of physicians and 79% of residents decreased the amount of medication prescribed when 
they consulted the OARRS program. This work is important as it shows that supervising 
physician behavior can have a direct positive influence on those around them. Since PAs work 
with a supervising physician (directly or indirectly) this is a factor that may influence physician 
assistant awareness and utilization of state prescription drug monitoring programs. Similarly, 
Schneider et al. (2009) found that physicians and other medical providers were more likely to 
follow proper hand hygiene practices if those practices were demonstrated by their supervisors.  
Another study by Feldman and colleagues (2011) found 84% of physicians surveyed had 
awareness of the OARRS and only 58.8% of those physicians utilized the OARRS. Reasons 
cited for accessing OARRS included suspicion of diversion (49%), suspicion of abuse (47%), 
additional information (3%), and job requirement (17%).  
Barrett and Watson (2003) examined physicians in Virginia and their awareness and 
utilization of a prescription drug monitoring program and found less than half the physicians 
were aware of the program. “Of the identified physicians that were aware of the prescription 
drug monitoring program, only 11% reported utilization of the program” (Barrett & Watson, 
2003, p. 8). 
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Physician Assistants’ Role in Prescription Drug Monitoring Programs 
PAs are licensed independent practitioners. Subsequently, they can perform physical 
examinations, diagnose and treat illnesses, order and interpret lab tests, perform procedures, 
assist in surgery, provide patient education and counseling, and make rounds in hospitals and 
nursing homes. PAs work in all medical fields including, but not limited to, family medicine, 
internal medicine, obstetrics and gynecology, pediatrics, general surgery, emergency medicine, 
psychiatry, and surgical subspecialties. PAs work in all settings including government, private, 
urban, rural, non-profit, group practice, solo practice, hospitals, and education.  
O’Connor (2009) states “Health professionals who are not physicians often have more 
time to guide, support and monitor patients. Better educated patients can make better-informed 
decisions about taking prescribed medications and often adhere more closely to treatment 
regimens.” O’Connor agrees that PAs increase accessibility, choice, and quality of care for 
patients.  
Data from Hooker and colleagues’ (2011) study showed overall supply of PAs is likely to 
increase by 72% to 127,821 PAs by 2025. This estimate of PA profession growth may lead 
policy makers to revise PAs’ prescriptive policy to allow the most cost effective and efficient use 
of PAs to bridge the medical care gap. With the potential policy revision, thought needs to be 
given to incorporating knowledge and utilization of state prescription drug monitoring programs.  
Prescription drug monitoring programs allow for a more educated approach to 
prescribing controlled substances. Informed decisions may be made about what controlled 
substances a patient has taken, how much, how often, and who is prescribing the medications. 
This information enhances the patient compliance. White and Davis (1999, p. 959) found that 
“The delegation of prescriptive authority based upon the discretion of the supervising physician 
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has proven to be a safe practice. There has been no record of significantly increased liability or 
malpractice claims due to PA prescribing.” 
Physician Assistant Pharmacologic Education 
In the State of Ohio, PAs must qualify for and obtain a certificate to prescribe. To apply 
for a certificate to prescribe, the Ohio Board of Medicine requires the following: (a) transcript 
verification of a Masters Degree that is clinically relevant to the PA profession; (b) thirty 
pharmacology-specific CME hours (accredited by either the American Academy of Physician 
Assistants or the Accreditation Council for Continuing Medical Education); (c) fifteen fiscal and 
ethical CME hours; and (d) twenty clinical hours (American Academy of Physician Assistants, 
2013; Ohio Association of Physician Assistants, 2013; State Medical Board of Ohio, 2013).  
PAs are required to collect 100 continuing medical education (CME) credits a year to 
maintain a national certification. Ohio law requires that in addition to the 100 hours of CME, 
there must be 12 hours of CME specific to pharmacologic updates. This requirement helps to 
ensure that once receiving the prescriptive authority from the state, a PA must stay current on 
contemporary pharmacologic treatments (American Academy of Physician Assistants, 2013; 
Ohio Association of Physician Assistants, 2013; Medical Board of Ohio [Continuing Medical 
Education], 2013). 
It is discretionary and not mandatory that a PA supervisory plan include guidelines for 
checking OARRS. The PA supervisory plan is developed by the PA, the supervising physician 
and possibly the employing entity and may include guidelines for the circumstances and degree 
of collaboration necessary for checking OARRS or consultation prior to prescribing or 
personally providing scheduled medications to a patient (State Medical Board of Ohio, 2011). 
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Ohio Governor John Kasich helped spearhead the development of the Governor’s 
Cabinet Opiate Action Team (GCOAT) for Prescriber Education. GCOAT created a continuing 
education video to provide information to health care professionals regarding the Guidelines for 
Prescribing Opioids for the Treatment of Chronic, Non-Terminal Pain (State Medical Board of 
Ohio; Opiate Action Team, 2013). The Guidelines have been adopted by the Medical Board, 
Nursing Board, Pharmacy Board and Dental Board and establish a trigger point for re-assessment 
of chronic pain patients receiving opioids at certain levels for 90 days or longer (State Medical 
Board of Ohio; Opiate Action Team, 2013). GCOAT helped fund community-based prescription 
drug abuse prevention coalitions, promote education of prescribers, and assist with registration of 
prescribers with the OARRS program (Governor’s Cabinet Opiate Action Team, 2013). The 
United States General Accounting Office (GAO-04-524T, 2004) found some PDMP’s provided 
limited educational sources for physicians and the public. Barrett and Watson (2003) agree that 
all educational efforts regarding prescription drug monitoring programs must include PAs as well 
as other providers and the public.  
Summary 
A review of the literature indicates that there has been some study of awareness and 
utilization of prescription drug monitoring programs in areas such as emergency medicine, pain 
management, psychology, and physician utilization. Literature also revealed a severe under-
utilization of the OARRS program (Woodworth, 2013). In 2010, Foxhall found that only 20% of 
prescribers were signed up to use OARRS. The Columbus Dispatch (2010) found similar results 
reveling that approximately 13% of Ohio’s licensed providers were registered to use OARRS. 
No research has explored awareness and utilization of the Ohio Automated Rx Reporting System 
by PAs.  
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In light of the mixed results showing both positive and negative effects of state 
prescription drug monitoring programs, future studies should evaluate whether the findings 
reflect reduction in abuse and diversion or suboptimal pain treatment (Curtis et al., 2006). 
The number of PAs who have prescriptive rights is rising, and an increasing number of 
states have prescription drug monitoring programs, both factors dictate a need to explore and 
understand the awareness and utilization of state prescription drug monitoring programs by PAs. 
The mixed results of earlier research on the awareness and utilization of a state prescription 
monitoring program and a lack of studies directly related to physician assistants give reasons for 
further investigation of the awareness and utilization of the Ohio Automated Rx Reporting 
System by physician assistants.  
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CHAPTER 3 
METHODOLOGY 
Procedures 
This study utilizes a quantitative approach to explore the following research questions: 
(a) Are physician assistants actively licensed to practice in Ohio aware of (enrolled in) the 
OARRS program?; (b) Do physician assistants actively licensed to practice in Ohio utilize the 
OARRS program?; (c) Do any factors predict enrollment or utilization of the OARRS program 
by physician assistants actively licensed to practice in Ohio?; and (d) Do physician assistants 
enrolled in OARRS alter their prescribing practices based on results of OARRS reports?   
 PAs actively licensed to practice in the State of Ohio (N = 2,563) as of February 25, 
2014, were contacted to participate in this study. A previously created, validated, and 
implemented questionnaire (Appendix D) by Ulbrich et al. (2010) used with permission, was 
adapted, and distributed to physician assistants actively licensed to practice in the State of Ohio 
as of February 25, 2014. This study was limited and cannot be generalized to all PAs or all state 
prescription monitoring programs.  
 The present author utilized the adapted questionnaire to examine the awareness and 
utilization of the Ohio Automated Rx Reporting System by physician assistants. Data included 
age, gender, years in practice, primary setting, primary specialty, current enrollment in OARRS, 
number of OARRS reports requested in past month, frequency of OARRS access, reason for 
requesting OARRS report, medication denied from OARRS results, supervising physician 
notified based on OARRS results, importance of OARRS in prescribing decision, reason for 
enrolling in OARRS, reason for accessing OARRS, reason if not enrolled in OARRS, education 
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about OARRS, knowledge of the OARRS, access to internet, specialty training, and state of 
graduate school.  
After receipt and tabulation of the data from the PAs actively licensed to practice in the 
State of Ohio, the data was statistically analyzed both descriptively and inferentially.  
Research partners. The following people committed to assist in this research design: 
1) Safdar Khan, M.D. Chief of Orthopaedic Spine Surgery at The Ohio State University 
Wexner Medical Center. Dissertation committee member.  
2)  The primary investigator Timothy Ulbrich (cf. Ulbrich, 2010) was contacted and 
permission gained for use of their research questionnaire.  
3) Ohio Board of Medicine was contacted to obtain public record list of actively 
licensed physician assistants in the State of Ohio and their contact information. 
Selection of subjects. Actively licensed PAs in the State of Ohio were asked to 
participate in this study. This study was limited to actively licensed PAs due to increased 
likelihood of utilization and awareness of OARRS. The Ohio Board of Medicine was contacted 
electronically February 25, 2014 (Appendix G) and the number of actively licensed PAs in Ohio 
was reported as 2,563. The Ohio Board of Medicine provided a list of those actively licensed 
PAs and their electronic contact information for research purposes only. 
Of the 2,563 PAs actively licensed in Ohio, only 2,386 had email addresses on file with 
the Ohio board of medicine. An email consisting of a cover letter with an electronic link to the 
consent form and the questionnaire (Appendix B, C, D respectively) were created and sent 
electronically to each PA actively licensed to practice in the State of Ohio as of February 25, 
2014.  
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 Prior to participating in the study, each PA read and marked a box to indicate informed 
consent and willingness to participate in the voluntary study. Marking was used instead of a 
signature to keep confidentiality at its highest. The informed consent form, which can be found 
in Appendix C, is in accordance with the University of New England Human Subject Review 
Board for the protection of Human Subjects (Appendix E). The participants consented and then 
completed surveys voluntarily and anonymously.  
Stakeholders. What follows are a list of potential stakeholders who may be impacted by 
the present research. 
1) Physician assistants licensed to practice in Ohio: The OARRS is a vital tool to 
physician assistants who prescribe scheduled medications in Ohio. 
2) Physician assistants in states with prescription drug monitoring programs: Awareness 
and utilization trends of prescription drug monitoring programs by physician assistants 
are of interest to physician assistants who prescribe scheduled medications in states 
with those programs. 
3) Employers of physician assistants in states with prescription drug monitoring 
programs: Awareness and utilization trends of prescription drug monitoring programs 
by physician assistants are of interest to employers of physician assistants who 
prescribe scheduled medications as it could affect policy/procedures and may also 
reduce diversion and misuse. 
4) Patients: Awareness and utilization trends of prescription drug monitoring programs of 
physician assistants may increase access to desperately needed scheduled medications 
prescribed safely. 
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5) Ohio Automated Rx Reporting System: Awareness and utilization trends of the 
OARRS by physician assistants are of interest for the shaping of current or future 
policy regarding use of the OARRS, physician assistant prescribing rights, and current 
or future continuing education seminars and information.  
6) Ohio Opiate Action Team: This team can provide data specific to the State of Ohio. 
They have established opioid prescribing guidelines for Ohio. The Ohio Opiate Action 
Team has access to Ohio providers in different areas, including physicians, 
pharmacists, law enforcement, and others. The team can aid in dissemination of 
results.  
7) State Medical Board of Ohio: The State Board has access to Ohio providers in 
different areas such as physicians, pharmacists, law enforcement, and others. They can 
aid in dissemination of results. 
Biases. The principal investigator was a currently licensed PA in the State of Ohio who 
uses the OARRS. The principal investigator treats a high volume of patients with pain 
complaints. The 26-question, self-reported survey that was developed by Ulbrich and colleagues 
(2010) was used with permission and adapted for physician assistants. (Appendix D, Appendix 
E).  
Limitations of the study. What follows are potential limitations to the present study. 
1) The study was limited to the participating physician assistants actively licensed to 
practice in the State of Ohio. Therefore, findings from this study cannot be 
generalized to all physician assistants or physician assistants in other states.  
2) The study was limited to physician assistants. Therefore this study does not represent 
all medical providers in the State of Ohio. 
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3) The completion of the survey was voluntary. Therefore some physician assistants 
choose not to complete the questionnaire, thus limiting sample size. 
4) The responses were self-reported.  
Basic assumptions. The following were the basic assumptions of the design: 
(a) The questionnaire respondents’ interpretation of the questions was accurate; (b) The 
questionnaire respondents answered in an honest and thoughtful manner; (c) An existing research 
tool developed by Ulbrich et al. (2010) was used with permission and adapted for PAs; and (d) 
The questionnaire was previously tested for validity by Ulbrich and colleagues.  
Instrumentation 
 The awareness and utilization of the Ohio Automated Rx Reporting System by PAs was 
assessed using a twenty-six-question self-reported survey that was developed by Ulbrich et al. 
(2010). The questionnaire was used with permission and adapted for PAs (Appendix D). All PAs 
actively licensed to practice in the State of Ohio with an email address on file as of February 25, 
2014 were contacted electronically and asked to voluntarily participate in this study.  
The survey contained questions regarding factors influencing enrollment or non-
enrollment, impact of OARRS on daily practice, previous OARRS education received 
knowledge of OARRS, and demographics. Skip-logic (a method to direct the respondent to the 
next question based on response to the previous question) was used, and those enrolled in 
OARRS answered 25 questions and those not enrolled in OARRS answered 17 questions. Both 
groups answered a common set of 16 questions (one question regarding enrollment, two 
questions regarding OARRS education, three questions regarding knowledge of OARRS, nine 
demographic-type questions, and one open-ended question). Non-enrolled PAs answered an 
additional question regarding factors influencing non-enrollment and enrolled PAs answered two 
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additional questions regarding factors influencing enrollment, two questions on use of OARRS, 
and five questions on the impact of OARRS on daily practice. The survey contained three Likert 
scale questions (1 = not important at all; 3 = neither; 5 = very important) to assess the primary 
objective (factors influencing enrollment and utilization). No part of the survey identified the 
respondent. 
Pilot Study 
 A pilot study was conducted using three PAs at a large university-based medical center. 
Each participant voluntarily participated. The participants agreed to participate in the pilot study 
knowing that their responses were anonymous but that the researcher would be contacting each 
of the participants after the survey completion for feedback. The three participants received the 
same email that included the cover letter, and link to the consent form and electronic survey. The 
survey responses were collected via SurveyMonkey. After all three participants completed the 
survey they were contacted for feedback regarding the study. All three participants agreed that 
the email was clear and concise and that the research questions were clear. The three participants 
found that the language was clear in the twenty-six question survey and easy to access. The 
instructions were clear and the survey smoothly transitioned between questions. Without 
prompting, all three participants verbalized the importance of the potential outcome of the survey 
results. The participants felt that the questions were appropriate and effective for the subject 
matter.  
Data Collection 
This study examined the awareness and utilization of the Ohio Automated Rx Reporting 
System by PAs. The researcher utilized an online survey developed and administered via 
SurveyMonkey. The survey is a twenty-six question survey used with permission from Timothy 
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Ulbrich (cf. Ulbrich et al., 2010) and adapted for PAs. To increase response rate, a modified 
Dillman Tailored Design Method (this method encourages using multiple contacts for survey 
type research) was used (Dillman, 2009). The first round of email communication containing the 
cover letter and electronic survey link was sent November 1, 2014. A follow up email containing 
the same letter and electronic survey link was sent December 1, 2014.  
Data Analyses 
Quantitative analysis. The data from PAs’ responses were downloaded from 
SurveyMonkey as a .csv file. Data were converted to numerical—either scaled or ordinal—or 
nominal coding to facilitate analysis in SPSS. The data were examined first in relationship to the 
hypotheses and then further, if deemed appropriate.  
To assess PA awareness of the OARRS program, descriptive statistics were used and 
delineated PAs into two categories of enrolled in the OARRS or not enrolled in the OARRS.  
To evaluate if PAs utilized the OARRS, the data were further examined using descriptive 
statistics to determine if the PAs’ were actively utilizing (had requested at least one OARRS 
report in the last twelve months) the OARRS or not.  
 Potential factors influencing a PA’s decision to enroll in OARRS or not were considered 
using several statistical methods. Descriptive statistics from ranking of factors influencing a 
decision not to enroll were reviewed. The Wilcoxon Signed-Rank test was used for further 
analysis of the reported importance of factors influencing decision to enroll or to not enroll in the 
OARRS and compared factors to identify significant differences in influence.  
 Multinomial logistical regression was used to decide if relationships exist between 
demographic information (self-reported specialty, previous OARRS education and the PAs’ 
decision to enroll in OARRS. A five-way loglinear analysis was performed to determine a 
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hierarchical unsaturated model for the associations among enrollment, specialized training in 
pain management, pain management in the daily setting, graduate of Ohio program, and gender. 
Finally, ordinal regressions were run to see if there is a relationship between the PAs’ decision to 
enroll in OARRS and years of practice or the knowledge of the OARRS and the likelihood that 
participants have enrolled. 
 Potential factors influencing a PA’s decision to use the OARRS or not were considered 
using several statistical methods. Descriptive statistics from ranking of factors influencing a 
decision to use OARRS were reviewed. The Wilcoxon Signed-Rank test and a logistic regression 
were used for analysis of the reported importance of factors influencing the PA’s decision to 
utilize the OARRS.  
 Descriptive statistics were used to determine if a PA altered their prescribing plan based 
on OARRS results. 
Secondary analysis. A comparison of importance of common factors influencing 
enrollment in OARRS was completed using descriptive statistics. Examination of relationships 
between the PAs decision to enroll in OARRS or not and preferences for OARRS education 
format was evaluated. A Pearson chi-square test for association was conducted between 
enrollment status and preference for education about the OARRS. The Mann-Whitney U Test 
was used to compare frequency of use of the OARRS to drug schedule most often leading to a 
request for an OARRS report, the decision to deny medication based on the report, contacting a 
supervising physician based on the finding in a report, and the use of OARRS by the supervising 
physician. Continued analysis was done using the Kruskal-Wallis H Test. The self-reported  
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frequency of use OARRS by the PA was compared to the self-reported influence of the factors 
on the decision to use the OARRS. 
 SPSS software was used by the researcher. All statistics were set at the .05 level of 
significance. 
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CHAPTER 4 
RESULTS 
 
The purpose of this chapter is to report and discuss the results of the statistical analysis as 
they pertain to the hypotheses. The data were acquired through the development, collection, and 
analysis of the survey responses. The study investigated the awareness and utilization of the 
Ohio Automated Rx Reporting System by physician assistants. This chapter is divided into the 
following sections: (1) rate of return; (2) hypotheses testing; (3) secondary analysis; and (4) 
summary. 
Rate of Return 
The twenty-six question, self-reported survey was uploaded to SurveyMonkey and an 
electronic link to the survey. Upon reviewing the list of actively licensed PAs provided by the 
State of Ohio Medical Board (N = 2,563 as of February, 25, 2014), it was found that 173 PAs did 
not provide an email and 43 of the email addresses were duplicates. After removing myself from 
the email list and adjusting for the aforementioned changes, on November 1, 2014 a first round 
email was sent to 2,346 PAs licensed in the State of Ohio. Of those 2,346 email addresses, 52 
emails were returned as undeliverable. Subsequently those unusable email addresses were 
removed and 2,294 PAs were sent a second round email reminder on December 1, 2014 that 
again contained the electronic survey link. Additionally after the second round, ten emails 
returned undeliverable. As of December 13, 2014, 359 PAs responded to the, a response rate of 
15.6%. A follow up email was sent to all the PAs’ emails. PAs who had previously responded 
were not excluded. Therefore, there is no way to determine if a PA completed the survey more 
than once.  
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 Descriptive statistics. Of the sample respondents (N = 355), 64.54% were female and 
35.46% were male and 65.81% of the respondents reported graduating from a PA school in the 
State of Ohio. Just over half (53.99%) of the respondents reported they do not practice in a 
setting where they assist with pain management on a daily basis. The majority (94.89%) of the 
respondents reported they have not completed any specialized training in pain management.  
 Years of practice as a physician assistant had the following breakdown among 
respondents; 32.59% reported practicing from 1–5 years, 24.28% for 6–10 years, 22.68% for 11–
15 years, 8.95% for 16–20 years, 3.51% for 21–25 years, 3.51% for 26–30 years, and 4.47% for 
30 or more years.  
 When asked about primary practice setting, the top three responses were not-for profit 
community hospital (33.55%), ambulatory care clinic (22.68%), and for profit hospital (16.29%). 
Government agency 1.28%, nursing home/long term care 0.96%, and home care organization 
0.00% were the least selected practice settings.  
 The top four specialties reported by respondents were emergency medicine (37.06%), 
family medicine (13.74%), internal medicine (12.14%), and orthopedics (10.54%). 
obstetrics/gynecology (1.92%), physiatry (1.60%), and infectious disease (0.32%) were the three 
least reported specialties.  
 Age was not included in the analysis model because it was highly correlated with years of 
practice. Access to the internet was also excluded from the analysis model as 99.68% of 
respondents reported having access to the internet at work. 
Analysis of hypotheses 
 Hypothesis one. A total of 2,346 of the 2,563 PAs actively licensed to practice in the 
state of Ohio were contacted to participate. Three hundred and fifty-nine PAs responded to the 
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survey. Of the 355 PAs who responded, 73.80% indicated that they were currently enrolled in 
OARRS and 26.20% indicated they were not enrolled in OARRS (it is understood that if a PA is 
not enrolled, then they were not using OARRS). For the purpose of this study awareness is equal 
to enrollment. With approximately three of four responding PAs reporting enrollment in the 
OARRS, null hypothesis number one; physician assistants actively licensed to practice in the 
state of Ohio are unaware of the OARRS should be rejected. 
 Hypothesis two. Of the 327 responses, 82 reported not being enrolled and therefore are 
not using the OARRS. Of the 245 PAs reporting enrollment in OARRS, 10 (4.08%) reported no 
use in the past month. This means 92 of the 327 PAs (28.13%) indicated not using the OARRS. 
Of the 235 PAs reporting use of the OARRS in the last month, 30.92% reported 1 to 5 requests, 
20.77% reported 6 to 10 requests, 21.74% reported 11 to 20 requests and 26.57% reported more 
than 20 requests for an OARRS report in the past month. Of the enrolled physician assistants 
utilizing OARRS, 74.04% reported average use the OARRS as weekly, daily, or for every 
controlled substance prescription. Of this same group, 25.96% reported average use the OARRS 
as rarely or at most monthly. 
 Data shows that 71.87% of responding physician assistants actively licensed to practice 
in the state of Ohio do utilize the OARRS and of those enrolled in OARRS, 74.04% report an 
average use of at least once per week. Based on the data, we must reject null hypothesis number 
two; physician assistants actively licensed to practice in the state of Ohio do not utilize the 
OARRS. 
 Hypothesis three. Potential factors influencing a PA’s decision to enroll in OARRS or 
not were considered using several statistical methods. Descriptive statistics from ranking of 
factors influencing a decision not to enroll were reviewed. The Wilcoxon Signed-Rank test was 
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used for further analysis of the reported importance of factors influencing decision to enroll or to 
not enroll in the OARRS and compared factors to identify significant differences in influence.  
 Multinomial logistical regression was used to decide if relationships exist between 
demographic information (self-reported specialty, previous OARRS education and the PA’s 
decision to enroll in OARRS. A five-way loglinear analysis was performed to determine a 
hierarchical unsaturated model for the associations among enrollment, specialized training in 
pain management, pain management in the daily setting, graduate of Ohio program, and gender. 
Finally, ordinal regressions were run to see if there is a relationship between the PA’s decision to 
enroll in OARRS and years of practice or the knowledge of the OARRS and the likelihood that 
participants have enrolled. 
Respondents not enrolled in OARRS were asked to rate the importance of seven factors 
influencing their decision not to enroll. The two the factors with the highest percentage of very 
important or somewhat important responses were understanding the law surrounding the OARRS 
database (54.88%) and usefulness to their practice (56.79%). The factors with the lowest 
percentage of very important or somewhat important responses were availability of internet 
access at work (30.49%) and concern with having to confront a patient if there is any suspicion 
of doctor shopping or drug abuse (28.05%). The data are summarized in Table 1.  
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Table 1 
 Factors Influencing the PA’s Decision Not to Enroll in the OARRS 
Factors Very 
Important or 
Somewhat 
Important 
Not 
Important or 
Somewhat 
Not 
Important 
Mean Standard 
Deviation 
Awareness of the OARRS 48.78% 25.61% 3.263 1.447 
     
Availability of internet access at 
work 
30.49% 47.56% 2.563 1.457 
     
Understanding of the law 
surrounding the OARRS 
54.88% 24.39% 3.463 1.449 
     
Concern with confronting 
patients 
28.05% 52.44% 2.538 1.359 
     
Usefulness to the practice 56.79% 25.93% 3.430 1.456 
     
Time available at work to access 
the OARRS 
48.78% 23.17% 3.375 1.325 
     
Time available to enroll in the 
OARRS 
50.00% 20.73% 3.400 1.327 
 
Respondents enrolled in OARRS were asked to rate the importance of seven factors 
influencing their decision to enroll. Overall, the highest importance was given to being able to 
assist with decreasing drug diversion (93.25%) and usefulness at the practice site (92.83%) or 
being able to assist with decreasing doctor shopping (92.38%). The factor that appears to be the 
least influential is education received about the OARRS (37.55%). The data are summarized in 
Table 2. 
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Table 2 
 Factors Influencing the PA’s Decision to Enroll in the OARRS 
Factors Very 
Important or 
Somewhat 
Important 
Not 
Important or 
Somewhat 
Not 
Important 
Mean Standard 
Deviation 
Education received about 
OARRS 
37.55% 43.04% 2.839 1.349 
     
Recommendation to enroll from 
colleague and/or employer 
75.53% 13.92% 3.928 1.228 
     
Knowledge of the law 
surrounding the OARRS 
database 
74.68% 8.02% 3.992 1.050 
     
Usefulness at your practice site 92.83% 3.80% 4.525 0.848 
     
Experience or situation at work 
using the OARRS 
83.12% 5.91% 4.232 1.017 
     
Being able to assist with 
decreasing drug diversion 
93.25% 1.27% 4.623 0.682 
     
Being able to assist with 
decreasing “doctor shopping” 
92.83% 2.11% 4.620 0.736 
 
The Wilcoxon Signed-Rank test was used for further analysis of the reported importance 
of factors influencing decision not to enroll in the OARRS and compared factors to identify 
significant differences in influence. Seven items were rated by not enrolled respondents to 
identify factors that that may have influenced their non-enrollment decision. These were (1) 
awareness of the OARRS, (2) availability of internet access at work, (3) understanding of the law 
surrounding the OARRS, (4) concern with confronting patients, (5) usefulness to the practice, (6) 
time available at work to access the OARRS and (7) time available to enroll in the OARRS.  
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Education received about the OARRS was significantly less important than all other 
choices (each p < 0.001). The ability to assist with decreasing drug diversion was significantly 
more influential than education received about the OARRS (Z = -11.51, p < 0.001), 
recommendation to enroll from a colleague or employer (Z = -7.27, p<0.001), knowledge of the 
associated laws (Z = -7.39, p < 0.001), and experience or situation at work using the OARRS (Z 
= -5.71, p < 0.001). Similarly, being able to assist with decreasing “doctor shopping” was 
significantly more influential than education received about the OARRS (Z = -11.34, p < 0.001), 
recommendation to enroll from a colleague or employer (Z = -7.30, p < 0.001), knowledge of the 
associated laws (Z = -7.15, p < 0.001), and experience or situation at work using the OARRS (Z 
= -5.82, p < 0.001). Usefulness at the practice site was found to be significantly more influential 
than education received about the OARRS (Z = -10.96, p < 0.001), recommendation to enroll 
from a colleague or employer (Z = -6.11, p < 0.001), knowledge of the associated laws (Z = -
6.15, p < 0.001), and experience or situation at work using the OARRS (Z = -5.03, p < 0.001).  
The Wilcoxon Signed-Rank test was used for similar analysis of the reported importance 
of factors influencing a decision to enroll in the OARRS and compared factors to identify 
significant differences in influence. Seven items were rated by enrolled respondents to identify 
factors that that may have influenced enrollment. These were (1) education received about the 
OARRS, (2) recommendation to enroll from a colleague or employer, (3) knowledge of the 
associated laws, (4) usefulness at the practice site, (5) experience or situation at work using the 
OARRS, (6) ability to assist with decreasing drug diversion and (7) being able to assist with 
decreasing “doctor shopping.” The three strongest factors in order of greatest influence were (6) 
ability to assist with decreasing drug diversion, (7) being able to assist with decreasing “doctor 
shopping,” and (4) usefulness at the practice site, respectively. 
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Table 3 
Factors Influencing Enrollment in the OARRS for PAs Already Enrolled 
Factors Mean Standard 
Deviation 
Education received about the OARRS 2.839 1.345 
Recommendation to enroll from a colleague or employer 3.928 1.228 
Knowledge of the associated laws 3.992 1.050 
Usefulness at the practice site 4.525 0.848 
Experience or situation at work using the OARRS 4.232 1.017 
Ability to assist with decreasing drug diversion 4.632 0.682 
Being able to assist with decreasing “doctor shopping” 4.620 0.736 
 
Using the Wilcoxon Signed-Rank test, analysis of the reported importance of factors 
influencing decision to enroll in the OARRS compared factors to identify significant differences 
in influence. Education received about the OARRS was significantly less important than all other 
choices (each p < 0.001). The ability to assist with decreasing drug diversion was significantly 
more influential than education received about the OARRS (Z = -11.51, p < 0.001), 
recommendation to enroll from a colleague or employer (Z = -7.27, p < 0.001), knowledge of the 
associated laws (Z = -7.39, p < 0.001), and experience or situation at work using the OARRS (Z 
= -5.71, p < 0.001). Similarly, being able to assist with decreasing “doctor shopping” was 
significantly more influential than education received about the OARRS (Z = -11.34, p < 0.001), 
recommendation to enroll from a colleague or employer (Z = -7.30, p < 0.001), knowledge of the 
associated laws (Z = -7.15, p < 0.001), and experience or situation at work using the OARRS (Z 
= -5.82, p < 0.001). Usefulness at the practice site was found to be significantly more influential 
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than education received about the OARRS (Z = -10.96, p < 0.001), recommendation to enroll 
from a colleague or employer (Z = -6.11, p < 0.001), knowledge of the associated laws (Z = -
6.15, p < 0.001), and experience or situation at work using the OARRS (Z = -5.03, p < 0.001).  
A multinomial logistical regression was run to examine prior education about the 
OARRS and the self-reported specialty. Four specialties, infectious disease (n = 1), pediatrics (n 
= 7), physiatry (n = 5), and psychology (n = 7), were removed due to low reporting. The results 
suggest that four statistically significant prior education factors may predict enrollment in the 
OARRS by PAs. The factors are prior education received through continuing education (CE)—
live or printed (p = .009), workplace education (p = .010), and State Board of Medicine 
newsletter (p = .019). None of the self-reported specialties were found to be significant.  
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Table 4 
Relationship of PAs’ Enrollment to Specialty and Prior Education about the OARRS  
Parameter Estimates 
 
95% Confidence 
Interval for 
Exp(B) Enrollment 
B Std. Error Wald df Sig. Exp(B) 
Lower 
Bound 
Upper 
Bound 
Intercept -3.563 1.759 4.104 1 .043  
 
  
Specialty: 
[1-Anesthesia] -1.528 1.401 1.189 1 .275   .217 .014 3.381 
[2-Cardiology] 2.280 1.394 2.674 1 .102  9.776 .636 150.269 
[3-Emergency 
Medicine] 
-.742 .932 .634 1 .426 .476 .077 2.956 
[4-Family Medicine] -.198 .981 .041 1 .840 .820 .120 5.609 
[5-General Surgery] -.174 1.036 .028 1 .866 .840 .110 6.396 
[7-Internal 
Medicine] 
.337 .965 .122 1 .727 1.401 .211 9.287 
[8-Neurology] .274 1.169 .055 1 .814 1.316 .133 12.997 
[9-OB/GYN] .217 1.294 .028 1 .867 1.242 .098 15.677 
[10-Orthopedics] -.432 .992 .190 1 .663 .649 .093 4.537 
         
Previous Education: 
[None] .125 .513 .059 1 .808 1.133 .415 3.095 
[Lectures/college] -.405 .653 .385 1 .535 .667 .185 2.399 
[CE-live/printed] 1.482 .571 6.742 1 .009* 4.402 1.438 13.476 
[Workplace educ.] 1.073 .414 6.709 1 .010* 2.923 1.298 6.580 
[Supervising Phys.] .476 .426 1.252 1 .263 1.610 .699 3.710 
[State Bd. of Med. 
Newsletter] 
1.089 .465 5.487 1 .019* 2.971 1.195 7.391 
 
[Article/journal or 
magazine] 
-.086 .822 .011 1 .916 .917 .183 4.592 
Note. * p< .05
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A five-way loglinear analysis was performed to determine a hierarchical unsaturated model to 
compare associations between enrollment, specialized training in pain management, pain 
management in the daily setting, graduate of an Ohio PA program, and gender. A hierarchical 
loglinear analysis was used for secondary review. There were 307 participants who responded. 
This produced a model that included all main effects and two two-way associations of enrollment 
with specialized training, enrollment with pain management in the setting, enrollment with Ohio 
PA program, and enrollment with gender. The model had a likelihood ratio of χ2(2) =3.805, p = 
.956. Two statistically significant relationships appear, between enrollment and pain 
management training and Ohio PA program (p = .041), and enrollment with Ohio PA program (p 
= .023). 
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Table 5 
Associations Between PA Enrollment in OARRS, Specialized Pain Management Training, Pain 
Management in Setting, Ohio Program Graduate, and Gender 
Effect df Partial Chi-
Square 
Sig. 
Enrollment-Pain Mgt. Training-Daily Pain Mgt.-Ohio PA 
Program 
1 .000 1.000  
Enrollment-Pain Mgt. Training-Daily Pain Mgt.-Gender 1 .000 .998 
Enrollment-Pain Mgt. Training-Ohio PA Program-Gender 1 .360 .548 
Enrollment-Daily Pain Mgt.-Ohio PA Program-Gender 1 .497 .481 
Pain Mgt. Training-Daily Pain Mgt.-Ohio PA Program-
Gender 
1 .001 .979 
Enrollment-Pain Mgt. Training-Daily Pain Mgt. 1 1.584 .208 
Enrollment-Pain Mgt. Training-Ohio PA Program 1 4.185 .041* 
Enrollment-Daily Pain Mgt.-Ohio PA Program 1 1.418 .234 
Pain Mgt. Training-Daily Pain Mgt.-Ohio PA Program 1 .208 .649 
Enrollment-Pain Mgt. Training-Gender 1 1.364 .243 
Enrollment-Daily Pain Mgt.-Gender 1 1.523 .217 
Pain Mgt. Training-Daily Pain Mgt.-Gender 1 2.004 .157 
Enrollment-Ohio PA Program-Gender 1 1.836 .175 
Pain Mgt. Training-Ohio PA Program-Gender 1 2.439 .118 
Daily Pain Mgt.-Ohio PA Program-Gender 1 .708 .400 
Enrollment-Pain Mgt. Training 1 1.844 .174 
Enrollment-Daily Pain Mgt. 1 .045 .832 
Pain Mgt. Training-Daily Pain Mgt. 1 .039 .844 
Enrollment-Ohio PA Program 1 5.191 .023* 
Pain Mgt. Training-Ohio PA Program 1 .179 .672 
Daily Pain Mgt.-Ohio PA Program 1 .299 .585 
Enrollment-Gender 1 .026 .872 
Pain Mgt. Training-Gender 1 .148 .700 
Daily Pain Mgt.-Gender 1 .501 .479 
Ohio PA Program-Gender 1 .727 .394 
Enrollment 1 77.599 .000* 
Pain Mgt. Training 1 299.905 .000* 
Daily Pain Mgt. 1 1.725 .189 
Ohio PA Program 1 31.180 .000* 
Gender 1 24.996 .000* 
Note. * p< .05  
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The results of an ordinal regression suggest that no statistically significant relationship exists 
between the PA’s decision to enroll in OARRS and years of practice. 
Table 6 
Relationship of PA’s Decision to Enroll in OARRS and Years of Practice 
Variables in the Equation 
 B S.E. Wald df p Exp(B) 
Yrs of 
Practice 
-.019 .016 1.491 1 .222 .981 
Step 1a 
Constant 1.256 .199 39.767 1 .000* 3.512 
a. Variable(s) entered on step 1: Q20. 
Note. * p< .05 
A second binary logistic regression was performed to ascertain the effect knowledge of 
the OARRS on the likelihood that participants have enrolled. The logistic regression model was 
statistically significant, χ2(1) = 16.236, p < .0005. The level of knowledge about the OARRS 
may be a predictor of enrollment.  
 
Table 7  
The Effect of Knowledge of the OARRS on the Likelihood of Enrollment 
Variables in the Equation 
 B S.E. Wald df p Exp(B) 
Knowledge .347 .090 14.751 1 .000* 1.415 Step 1a Constant -1.471 .660 4.963 1 .026* .230 
a. Variable(s) entered on step 1: Knowledge. 
Note. * p< .05 
From this analysis, one may conclude that prior education through continuing education (CE)-
live/printed, workplace education, the State Board of Medicine Newsletter, receiving specialized 
pain management training, being a graduate of an Ohio PA program, and level of knowledge 
about the OARRS may be factors predicting enrollment in the OARRS. 
Based on the data, we must reject null hypothesis number three; no factors are predictive of 
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awareness of OARRS by physician assistants actively licensed to practice in the state of Ohio. 
 Hypothesis four. Potential factors influencing a PA’s decision to utilize OARRS were 
considered using several statistical methods. Descriptive statistics from ranking of factors 
influencing a decision to use OARRS were reviewed. The Wilcoxon Signed-Rank test and a 
logistic regression were used for analysis of the reported importance of factors influencing the 
PA’s decision to utilize the OARRS.  
Respondents enrolled in OARRS were asked to rate the importance of seven factors 
influencing their decision to utilize the database. These were (1) availability of internet access at 
the workplace, (2) knowledge of the laws surrounding the OARRS database, (3) concern with 
having to confront a patient if there is suspicion of doctor shopping or drug abuse, (4) 
prescribing behaviors of providers in local area, (5) usefulness to practice site, (6) time available 
at work to access an OARRS report, and (7) previous interactions with a patient. Descriptive 
statistics indicate the greatest percentage of very important or somewhat important influences 
were identified as usefulness at the practice site (91.14%) and availability of internet access at 
the workplace (88.19%). The factor that appears to be the least influential was prescribing 
behaviors in your local area (41.95%). Looking only at the PAs who are enrolled in the OARRS 
but utilizing the database (n = 8), the most influential factor (very important or somewhat 
important) was identified as knowledge of the OARRS database (100%) and the least influential 
was previous interactions with a patient (37.5%). The data are summarized in Table 8. 
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Table 8  
 Factors Influencing the PA’s Decision to Utilize the OARRS 
Factors Very 
Important or 
Somewhat 
Important 
Not 
Important or 
Somewhat 
Not 
Important 
Mean Standard 
Deviation 
Availability of internet access at 
the workplace 
88.19% 8.02% 4.414 1.003 
     
Knowledge of the laws 
surrounding the OARRS 
database 
72.88% 10.17% 3.890 1.180 
     
Concern with having to confront 
a patient if there is suspicion of 
doctor shopping or drug abuse  
62.45% 30.385 3.532 1.550 
 
     
Prescribing behaviors of 
providers in local area 
41.95% 30.15% 3.123 1.374 
     
Usefulness to practice site 91.14% 2.53% 4.443 0.777 
 
Time available at work to access 
an OARRS report 
70.89% 14.77% 3.781 1.212 
 
 
Previous interactions with a 
patient 
76.69% 13.14% 3.919 1.223 
 
 The Wilcoxon Signed-Rank Test was used for further analysis of the medians of the 
reported importance of factors influencing the PA’s decision to utilize the OARRS and compared 
the seven factors to identify significant differences in influence.  
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Table 9 
Comparison of Medians for Rating of Influences for PA’s Decision to Use OARRS 
 
Knowledge 
of  
OARRS 
laws 
Patient 
confrontation 
Prescribing 
behaviors 
Value to 
practice 
Time 
available  
to access 
Previous 
patient 
interaction 
 
Internet 
access at 
work 
 
Z=-6.018 
p=.000* 
 
Z=-7.008 
p=.000* 
 
Z=-9.127 
p=.000* 
 
Z=.204 
p=.838 
 
Z=-6.596 
p=.000* 
 
Z=-4.847 
p=.000* 
 
 
Knowledge  
of OARRS  
laws 
  
Z=-3.057 
p=.002* 
 
Z=-6.431 
p=.000* 
 
Z=6.008 
p=.000* 
 
Z=-1.054 
p=.292 
 
Z=.546 
p=.585 
 
 
Patient  
confrontati
on  
   
Z=-3.089 
p=.002* 
 
Z=7.631 
p=.000* 
 
Z=2.379 
p=.017* 
 
Z=3.673 
p=.000* 
 
Prescribing 
behaviors  
    
Z=10.099 
p=.000* 
 
Z=5.535 
p=.000* 
 
Z=6.932 
p=.000* 
 
Value to  
practice  
     
Z= -7.212 
p=.000* 
 
Z= -6.260 
p=.000* 
 
Time 
available  
to access  
      
Z=1.450 
p=.147 
Note. * p< .05 
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The results of the Wilcoxon Signed-Rank Test allow us to compare median difference of 
factors influencing the decision to use OARRS. The ranking of the factors from most influential 
to the least for the decisions to use the OARRS are: usefulness to practice site, availability of 
internet access at the workplace, previous interactions with a patient, knowledge of the laws 
surrounding the OARRS database, time available to access a report, concern with confronting a 
patient, and prescribing behaviors of local providers. 
 A logistic regression was used to examine the relationships between use and non-use by 
enrolled PAs and the seven influences. From this, the only factor with statistical significance is 
usefulness to the practice (p = .013). However, knowledge of the laws surrounding the OARRS 
database (p = .070) may be of interest. 
From this analysis, one may conclude that usefulness to practice site and availability of 
internet access at the workplace may be factors predicting use of the OARRS. Based on the data, 
we must reject null hypothesis number four; no factors are predictive of utilization of OARRS by 
physician assistants actively licensed to practice in the state of Ohio. 
 Hypothesis five. Descriptive statistics were used initially to determine if results from an 
OARRS report would alter the prescriptive plan of the PA. For this analysis, the responses were 
confined to those who are both enrolled and utilizing the OARRS. Schedule II or Schedule III 
drugs were identified by 94.45% of these respondents as most often leading them to request an 
OARRS report. Table 10 shows what schedule of medication most often prompted an enrolled 
PA to request an OARRS report.  
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Table 10 
Drug Types Most Likely Leading to Request of OARRS Report 
Drug Schedule  Number   Percentages 
Schedule II 159 67.95% 
Schedule III 62 26.50% 
Schedule IV 11 4.70% 
Schedule V 2 0.85% 
No Response 2 0.85% 
Note. Only PAs enrolled in OARRS responded. 
 
Responses also indicate 90.25% of these PAs have denied prescribing medications to a 
patient based on an OARRS report and 83.47% responded that they have contacted a supervising 
physician based on the findings on an OARRS report. 
The PAs enrolled in and utilizing OARRS were asked about the importance of the 
OARRS report in the decision process when precribing controlled medications. Figure 1 
illistrates the preceived importance of running an OARRS report when precribing controlled 
medications. 
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Figure 1. The importance of OARRS report when prescribing controlled substances. It is 
important to note that only PAs enrolled in OARRS responded. 
 
 In summary, 84.47% of the utilizing PAs consider the OARRS report very important or 
somewhat important to the decision process when dispensing a prescription for controlled 
substances, 90.25% indicate they have denied prescribing medications to a patient based on an 
OARRS report, and 83.47% responded that they have contacted a supervising physician based on 
the findings on an OARRS report. From this analysis, one may conclude that the majority of 
enrolled and utilizing PAs have altered their prescribing plans based on the findings of an 
OARRS report. Based on the aforementioned data, we must reject null hypothesis number five; 
physician assistants actively licensed to practice in the state of Ohio do not alter their prescribing 
plans as a result of utilization of OARRS. 
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Secondary Analysis 
Following examination of the five hypotheses, secondary analysis was undertaken. The 
purpose is to explore data in a manner that might not be directly supportive of the hypotheses. A 
closer look at two questions asked of both enrolled and non-enrolled users was of interest. Each 
rated the importance of common factors influencing enrollment or non-enrollment in OARRS. 
Descriptive statistics highlight notable differences in importance of these two common factors 
influencing a PA’s decision to enroll in OARRS or not; knowledge of laws about OARRS use 
and usefulness of OARRS to the PA’s practice. Table 11 shows the results. This difference could 
be further explored in future research. 
Table 11 
Comparison of Importance of Common Factors Influencing Enrollment in OARRS 
 
Knowledge of 
Laws 
Usefulness to 
Practice 
 
Not 
Enrolled Enrolled 
Not 
Enrolled Enrolled 
 n=82 n=237 n=81 n=237 
Median 4 4 4 5 
Mean 3.451 3.992 3.407 4.525 
SD 1.467 1.050 1.447 0.848 
Very important or 
somewhat important 54.88% 74.68% 56.79% 92.83% 
Not important or 
somewhat not important 24.39% 8.02% 25.93% 3.80% 
 
            
 
56 
 Using descriptive statistics, a comparison of preferences for OARRS education by 
enrolled and non-enrolled PAs was explored. Figure 2 illustrates the findings.  
 
Figure 2. Preference for types of education about OARRS. 
 
 A Pearson chi-square test for association was conducted between enrollment status and 
preference for education about the OARRS (see Table 12). All expected cell frequencies were 
greater than five. There was a statistically significant association between enrollment and 
preference for each of three different types of education: law continuing education about the 
OARRS, χ2(1)= 5.285, p=.022, Phi (φ)= .127, live general continuing education, 5.623, p=.032, 
Phi (φ)= .119 and mailed brochure, χ2(1)= 12.204, p<.001, Phi (φ)= -.193. 
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Table 12 
Association between Enrollment Status and Preferences for Education about the OARRS 
Type of Education about OARRS Chi Square Sig.  
Law CE χ2(1)= 5.285 p=.022* Phi (φ)= .127 
Live General CE χ2(1)= 5.623 p=.032* Phi (φ)= .119 
Workplace Education χ2(1)= 1.268 p=.260  
Printed CE χ2(1)= 1.606 p=.205  
Mailed Brochure χ2(1)= 12.204 p=.000* Phi (φ)= -.193 
State Board of Medicine Newsletter χ2(1)= .297 p=.586  
Article in Journal or Magazine χ2(1)= .060 p=.806  
Note. * p< .05 
 
The Mann-Whitney U Test (see Table 13.) was used to compare frequency of use of the 
OARRS to drug schedule most often leading to a request for an OARRS report, the decision to 
deny medication based on the report, contacting a supervising physician based on the finding in a 
report, and the use of OARRS by the supervising physician. The drug schedule most often 
leading to a request for an OARRS report (p=.068) does not show a statistically significant 
difference with frequency of use so this may suggest a significance between frequency of use 
and drug schedule most often leading to a request for an OARRS report. A statistically 
significant difference was found between the decision to deny medication based on the report 
(p=.000), contacting a supervising physician based on the finding in a report (.005), and the use 
of OARRS by the supervising physician (.002). A conclusion might be made that these three 
factors are not related to frequency of use.  
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Table 13 
Frequency of OARRS Use and the Rating of Factors on the PA’s Decision to Use OARRS 
 
Null Hypothesis: The distribution of Frequency of Use is the Same Across 
Categories of Factors 
Sig. 
  
Drug schedule most often leading to a request for an OARRS report .068 
  
Decision to deny medication based on the report .000* 
  
Contacting a supervising physician based on the finding in a report .005* 
  
Use of OARRS by the supervising physician .002* 
Note. * p< .05, Asymptotic significances are displayed. The significance level is .05. 
Continued analysis was done using the Kruskal-Wallis H Test (see Table 14). The self-
reported frequency of use OARRS by the PA was compared to the self-reported influence of the 
factors on the decision to use the OARRS. The knowledge of the laws surrounding the OARRS 
database (p = .340), prescribing behaviors of providers in the local area (p = .574), and time 
available at work to access and OARRS report (p = .707) were not statistically different from 
frequency of use. A conclusion might be made that these factors have statistically significant 
relationships to frequency of use. 
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Table 14 
 
Frequency of OARRS Use and the Rating of Influences on the PA’s Decision to Use OARRS 
 
Null Hypothesis: The distribution of Frequency of Use of OARRS is the Same 
Across Categories of Influences 
Sig. 
Availability of internet access at the workplace .002* 
  
Knowledge of the laws surrounding the OARRS database .340 
  
Concern with confronting a patient about suspected abuse or misuse  .000* 
  
Prescribing behaviors of providers in local area .574 
  
Usefulness to practice site .000* 
  
Time available at work to access an OARRS report .707 
  
Previous interactions with a patient .020* 
Note. * p< .05, Asymptotic significances are displayed. The significance level is .05. 
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CHAPTER 5 
DISCUSSION 
The primary purpose of this study was to examine the awareness and utilization of the 
Ohio Automated Rx Reporting System by physician assistants. The literature surrounding 
awareness of PDMPs and their use by medical providers is vague. Previous literature revealed a 
severe under-utilization of the OARRS program (Woodworth, 2013). In 2010, Foxhall found that 
only 20% of prescribers were signed up to use OARRS. The Columbus Dispatch (2010) found 
similar results reveling that approximately 13% of Ohio’s licensed providers were registered to 
use OARRS. No research had explored awareness and utilization of the Ohio Automated Rx 
Reporting System by PAs.  
With the number of PAs who have prescriptive rights rising, and mixed results of earlier 
research on the awareness and utilization of state PDMPs clear need for further investigation of 
the awareness and utilization of the Ohio Automated Rx Reporting System by physician 
assistants was identified.  
 All five null hypotheses were rejected (1) Physician assistants actively licensed to 
practice in the state of Ohio are unaware of the OARRS (2) Physician assistants actively licensed 
to practice in the state of Ohio do not utilize the OARRS (3) No factors are predictive of 
awareness of OARRS by physician assistants actively licensed to practice in the state of Ohio (4) 
No factors are predictive of utilization of OARRS by Physician assistants actively licensed to 
practice in the state of Ohio and (5) Physician assistants actively licensed to practice in the state 
of Ohio do not alter their prescribing plans as a result of utilization of OARRS). 
 Results indicated that 73.80% of Ohio PAs were currently enrolled in OARRS and 
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26.20% were not enrolled in OARRS. Data also showed that 71.87% of responding physician 
assistants actively licensed to practice in the state of Ohio do utilize the OARRS and of those 
enrolled in OARRS, 74.04% report an average use of at least once per week.  
From this analysis, one may conclude that desire to decrease drug abuse/misuse, prior 
education through continuing education (CE)-live/printed, workplace education, the State Board 
of Medicine Newsletter, receiving specialized pain management training and being a graduate of 
an Ohio PA program, being a graduate of an Ohio PA program, and level of knowledge about the 
OARRS may be factors predicting enrollment in the OARRS. Years of practice, and self-
reported specialties were not significant predictors of a PAs decision to enroll in OARRS.  The 
two the factors with the highest percentage in influencing a PAs decision not to enroll were 
understanding the law surrounding the OARRS database (54.88%) and usefulness to their 
practice (56.79%).  
From this analysis, one may surmise that OARRS usefulness to practice site and 
availability of internet access at the workplace may be factors predicting use of the OARRS. 
Based on the data, we must reject null hypothesis number four; no factors are predictive of 
utilization of OARRS by physician assistants actively licensed to practice in the state of Ohio. 
Results indicate that 84.47% of the utilizing PAs consider the OARRS report very 
important or somewhat important to the decision process when dispensing a prescription for 
controlled substances, and 90.25% indicate they have altered their prescribing plan and denied 
prescribing medications to a patient based on an OARRS report. 
Ohio House Bill 341 was passed in September 16, 2014 (Ohio Revised Code Sec 
4730.53. (A)- Sec. 4731.055. (E) of House Bill 341, 2014) stating that a prescriber of controlled 
substances must request and document the results of an OARRS report prior to prescribing any 
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medications. The aforementioned bill, combined with the results of this study, indicate a need to 
pursue further research in the area of utilization and awareness of the OARRS by PAs. 
Implications of the Limitations on Present and Future Research  
 Limitations to this research were identified. First, a response rate of 15.6%, although 
respectable for survey-type research, may limit the external validity of the results. Secondly, the 
accuracy of the email addresses provided by the State of Ohio Medical Board and the potential 
for the email to be routed to a “junk mail” box did not allow for an accurate assessment of the 
number of PAs receiving the survey. Therefore the response rate reported most likely 
underestimated the actual response rate. Third, the responses to the questions were self-reported 
and responses to questions about practice setting may be interpreted differently amongst the 
respondents. And lastly, although conclusions may be hypothesized to other states with 
prescription drug monitoring programs, the findings of this research were based on physician 
assistants in Ohio and the Ohio prescription drug monitoring program (OARRS).  
Recommendations 
  Practical application of results. In conclusion, initial efforts should be directed toward 
increasing PA awareness and enrollment in the OARRS. Specifically, education should be 
continued or developed focusing on law continuing education about the OARRS, providing live 
general continuing education, and utilizing a mailed brochure. This, in combination with CME 
focused on who should enroll in OARRS, how to use OARRS, when to use OARRS, and 
potential benefits of OARRS may enhance the safe and appropriate delivery of commonly 
abused and misused controlled medications.  
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Future research. Implications with respect to the results of this study warrant the 
following future research and policy recommendations: 
1. Future studies utilizing a replication of the present study should be pursued by 
obtaining information from other states that utilize a prescription drug monitoring 
program. 
2. Future studies utilizing a replication of the present study should be pursued by 
obtaining information from all providers who utilize the Ohio Automated Rx 
Reporting system. 
3. Future studies utilizing a replication of the present study should be pursued and 
further delineate the notable difference in importance of common factors influencing 
a PA’s decision to enroll in OARRS or not. 
4. In light of the mixed results showing both positive and negative effects of state 
PDMPs, future studies should evaluate whether PDMPS create reduction in abuse and 
diversion or suboptimal pain treatment (Curtis et al., 2006). 
5. The list of PAs kept by the State Board of Medicine should be updated more 
regularly to contact PAs to inquire if they are still practicing in Ohio and current 
contact information.  
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APPENDIX A 
DEA SCHEDULE OF MEDICATIONS 
 
DEA 
Schedule 
Abuse 
Potential 
Example Drugs Effects Medical 
Use 
 
 
I 
 
 
Highest 
 
 
Heroin, (LSD), Marijuana 
 
Unpredictable 
effects, severe 
psychological or 
physical 
dependence, death 
 
No 
accepted 
use 
 
 
 
II 
 
 
High 
 
Methylphenidate, 
morphine, methadone, PCP, 
codeine, cocaine, Demerol, 
oxycodone 
 
May lead to severe 
psychological or 
physical dependence 
 
Accepted 
use with 
restrictions 
 
 
III 
 
 
Medium 
 
Anabolic steroids, Tylenol 
with codeine, Ketamine 
May lead to 
moderate physical 
dependence or high 
psychological 
dependence 
 
 
Accepted 
use 
 
 
IV 
 
 
Low 
 
Diazepam, clonazapam, 
midazolam 
 
 
May lead to limited 
psychological or 
physical dependence 
 
Accepted 
use 
 
 
 
 
V 
 
 
Lowest 
 
Cough preparations 
containing codeine: 
Robitussin AC, Phenergan 
with Codeine 
 
May lead to limited 
psychological or 
physical dependence 
 
 
Accepted 
use 
 
(Drug Enforcement Agency: Office of Diversion Control, 2013).  
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APPENDIX B 
SURVEY COVER LETTER 
 
November 1, 2014 
 
Dear physician assistant: 
 
I would like to request your participation in a doctoral study examining awareness and utilization 
of the Ohio Automated Rx Reporting System (OARRS) by physician assistants. While your 
participation is voluntary and anonymous, know that your participation has the potential to 
greatly impact the PA profession. 
 
This survey is open to physician assistants actively licensed to practice in the State of Ohio. 
Physician assistants are being asked to complete a non-invasive twenty-six-question survey 
focused on use of the OARRS. Data will be beneficial to physician assistants within the state of 
Ohio, physician assistants in other states with prescription monitoring programs, as well as other 
medical providers in states with prescription drug monitoring programs.  
 
My major advisor and committee discussed and approved this project. My study received 
approval from the University of New England Institutional Review Board March 4, 2014. 
 
Please use the link below to complete the electronic survey and consent form by November 15, 
2014. If you have any questions or concerns, please contact me at (304) 559-7034 or 
jrose9@une.edu. Your participation is greatly appreciated. Thank you for your time and effort.  
  
Survey:  https://www.SurveyMonkey.com/s/OARRS 
 
Sincerely, 
 
Julia Rose, MSPAS, Principal Investigator 
PA-C at The Ohio State University Medical Center 
Doctoral Candidate University of New England 
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APPENDIX C 
CONSENT FORM 
 
Title:  Awareness and utilization of the Ohio Automated Rx Reporting System by physician 
assistants. 
Principle Investigator: Julia Rose 
Advisor: Michelle Collay, Ph.D. 
Department:  Education 
Address: University of New England 
   11 Hills Beach Road 
   Biddeford, Maine 04005 
 
WRITTEN CONSENT TO ACT AS A RESEARCH SUBJECT 
After reading the statement below, please indicate your consent by marking an X in the box on 
the consent in the survey. 
 
Statement of Procedure:   
 This study is a research project conducted for completion of doctoral candidacy 
for the University of New England. The purpose of this study is to examine the awareness 
and utilization of the Ohio Automated Rx Reporting System by physician assistants. Julia 
Rose, a physician assistant at Ohio State University Medical Center and Doctoral 
Candidate at the University of New England, is conducting the study. 
 For this study, participants will be asked to complete and return a survey 
consisting of twenty-six questions: age, gender, years in practice, primary setting, 
primary specialty, current enrollment in OARRS, number of OARRS reports requested in 
past month, frequency of OARRS access, reason for requesting OARRS report, 
medication denied from OARRS results, supervising physician notified based on OARRS 
results, importance of OARRS in prescribing decision, reason for enrolling in OARRS, 
reason for accessing OARRS, reason if not enrolled in OARRS, education about 
OARRS, knowledge of the OARRS, access to internet, specialty training, and state of 
graduate school. 
 All personal information will be kept confidential and voluntary. Participants who 
would like to obtain the results of this study may request them. If at any time during the 
study you need help, or have additional questions you can contact the investigator Julia 
Rose- jrose9@une.edu. 
 
I certify that I have read and understand the statement of procedure and agree to participate as a 
subject in the research described above. My participation is given voluntary and without being 
influenced. I understand that I may discontinue at any time without penalty or prejudice. I certify 
that I am at least 18 years of age. Your anonymous consent will be obtained on the first page of 
the survey.  
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If you have questions about your rights as a research participant, please contact Olgun Guvench, 
M.D. Ph.D., Chair of the UNE Institutional Review Board for the Protection of Human Subjects 
at (207) 221-4171 or by email at irb@une.edu. 
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APPENDIX D 
QUALIFICATION SURVEY 
 
Physician assistants actively licensed to practice in the State of Ohio 
 
Please answer the following questions to the best of your ability: 
 
Section I: Questions Regarding the Ohio Automated Rx Reporting System (OARRS) 
1. Are you currently enrolled in the Ohio Automated Rx Reporting System (OARRS)?  
Yes    No (please skip to section IV) 
⁪    ⁪   
2. How many patients have you requested an OARRS report for in the past month? 
0  1-5  6-10  10-20  >20 
⁪  ⁪  ⁪  ⁪  ⁪ 
3. On average, how often do you access the OARRS database? 
 
 For every controlled substance prescription 
 Daily 
 Weekly     
 Monthly       
 Rarely (less than once per month)  
 Never  
 
Section II: Impact of the OARRS on Daily Practice 
4. Since the start of the OARRS in 2006, which of the following has most often led you to 
request an OARRS report? 
Schedule II Schedule III Schedule IV Schedule V     
⁪  ⁪       ⁪       ⁪   
5. Have you ever denied medication(s) to a patient based on information obtained from the 
OARRS report? 
Yes No 
⁪  ⁪ 
6. Have you ever contacted a supervising physician based on your findings in an OARRS 
report? 
Yes No 
⁪  ⁪  
7. Does your supervising physician use OARRS? 
                 Yes             No Unsure 
                   ⁪              ⁪             ⁪ 
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When dispensing a prescription for controlled substances, how important is the OARRS report in 
your decision process? 
 Not important at all 
 Somewhat not important 
 Neither 
 Somewhat important 
 Very important 
 
Section III: Factors Influencing Enrollment (Already Enrolled) 
8. How important were the following in your decision to enroll in the OARRS (1=not 
important at all; 3=neither; 5 = very important)? 
___ Education received about the OARRS (lectures, CE, printed materials, etc). 
___ Recommendation to enroll from a colleague and/or employer. 
___ Knowledge of the law surrounding the OARRS database. 
___ Usefulness at your practice site. 
___ Experience or situation at work using the OARRS. 
___ Being able to assist with decreasing drug diversion. 
___ Being able to assist with decreasing “doctor shopping.” 
 
9. How important are the following in determining whether or not you access an OARRS 
report (1=not important at all; 3 = neither; 5 = very important,)?  Please skip to question 
11 after completing your answer.  
___ Availability of internet access at the workplace. 
___ Knowledge of the law surrounding the OARRS database. 
___ Concern with having to confront a patient if there is any suspicion of doctor 
shopping or drug abuse.  
___ Prescribing behaviors of providers in your local area. 
___ Usefulness to your practice site. 
___ Time available at work to access an OARRS report. 
___ Previous interactions with a patient. 
 
Section IV: Factors Influencing Enrollment in the OARRS (Not Enrolled) 
10. How important are the following in your decision not to enroll in the OARRS (1 = not 
important at all, 5 = very important, 3 = neither)? 
___ Awareness of the Ohio Automated Rx Reporting System (OARRS). 
___ Availability of internet access at work. 
___ Understanding of the law surrounding the OARRS database. 
___ Concern with confronting a patient regarding a prescription if there is any 
suspicion of doctor shopping and/or abuse. 
___ Usefulness to your practice site.  
___ Time available at work to access an OARRS report.  
___ Time available to enroll in the OARRS. 
            
 
79 
 
Section V: OARRS Education 
11. What type of education have you received regarding the OARRS? 
 None 
 Lectures or education during college 
 Continuing Education (CE) – live or printed 
 Workplace education 
 Supervising physician 
 State Board of Medicine newsletter 
 Article in a journal/magazine 
 Other (please specify)_________________________________________ 
 
12. Which of the following types of education would you most likely participate in to learn 
more about the OARRS?  Please check all that apply. 
 Law Continuing Education (CE) 
 Live General Continuing Education (CE) 
 Workplace education 
 Printed Continuing Education (CE) 
 Mailed brochure 
 State Board of Medicine newsletter 
 Article in a journal/magazine  
 
  Section VI: Knowledge of the Ohio Automated Rx Reporting System (OARRS) 
13. Which of the following medications are included in the OARRS database?  Please check 
all that apply. 
 Schedule II 
 Schedule III 
 Schedule IV 
 Schedule V 
 
14. Which of the following groups have access to an OARRS report?   Please check all that 
apply. 
 Pharmacists 
 Physician Assistants 
 Physicians 
 Law enforcement 
 Patients 
 
15. Physician Assistants enrolled to receive an OARRS report cannot distribute a copy of the 
report to the physician or patient.  
True False 
⁪    ⁪ 
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Section VII: Practice/Education Information 
16. What is your specialty? (select one) 
⁪  Anesthesia   ⁪  Cardiology              ⁪ Emergency Medicine 
⁪  Family Medicine ⁪  Infectious Disease  ⁪  Internal Medicine 
⁪  Neurology  ⁪  Orthopedics  ⁪  Pediatrics 
⁪  Physiatry  ⁪  Psychology  ⁪  General Surgery 
⁪  Obstetrics/Gynecology 
⁪  Other        
 
17. What is your current primary practice setting? (select one) 
 Ambulatory care clinic   
 College or university 
 Community (not for profit) hospital 
 For-profit hospital 
 Government agency 
 Government hospital 
 Home care organization 
 Integrated health system 
 Nursing home, skilled care, sub-acute or long-term care facility 
 Primary care clinic 
 University hospital 
 Other, please specify__________________________________________ 
 
18. Do you have access to the internet at your primary site of practice? 
Yes No 
⁪ ⁪ 
19. How many years have you been practicing as a physician assistant? 
1-5  6-10         11-15 16-20      21-25          26-30    >30 
⁪  ⁪          ⁪  ⁪        ⁪        ⁪       ⁪ 
20. Have you completed any specialized training (e.g. residency, certificate programs, etc) in 
pain management? 
Yes No 
⁪ ⁪ 
21. Do you practice in a setting where you assist with pain management on a daily basis? 
Yes No  
⁪ ⁪ 
22. Did you graduate from a physician assistant school in the state of Ohio? 
Yes No 
⁪ ⁪ 
 
Section VIII: Demographics 
23. What is your age? 
<30  30-39  40-49  50-59  >59 
⁪  ⁪                        ⁪  ⁪  ⁪ 
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24. What is your gender? 
Male Female 
⁪  ⁪ 
25. Please leave any additional comments you have regarding the OARRS database. 
___________________________________________________________________ 
___________________________________________________________________ 
 
 
If there are any questions please feel free to contact me at the following number: 
Julia Rose   
304-559-7034 (Cell)     
 
Adopted from:  
Ulbrich, T. R., Dula, C. A., Green, C. G., Porter, K., & Bennett, M. S. (2010). Factors 
influencing community pharmacists' enrollment in a state prescription monitoring 
program. Journal of the American Pharmacists Association, 50, 5. 
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APPENDIX E 
 
PERMISSION TO USE SURVEY INSTRUMENT 
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APPENDIX F 
 
LETTER OF APPROVAL FROM INTERNAL REVIEW BOARD 
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APPENDIX G 
EMAIL LETTER: OHIO BOARD OF MEDICINE 
 
February 25, 2014 
 
 
Dear Patrick Randall: 
 
Thank you so much for your assistance on the phone this morning. My name is Julia Rose. I am 
a physician assistant at OSU medical center. I am also a doctoral candidate at the 
University of New England.  
 
I propose to conduct a survey of physician assistants actively licensed to practice in the State of 
Ohio. The data collected will be in based upon the awareness and utilization of the Ohio 
Automated Rx Reporting System by physician assistants. Physician assistants are being 
asked to complete a non-invasive twenty-six-question survey. Data will be beneficial to 
physician assistants within the state of Ohio, physician assistants in other states with 
prescription monitoring programs, as well as other medical providers in states with 
prescription drug monitoring programs.  
 
I met with my major advisor previously to discuss this project.  
 
I would appreciate your assistance with obtaining the list of active physician assistants in the 
State of Ohio and their contact information. 
 
Number of active physician assistants in the State of Ohio: 2,563.  
 
My mail address is 7782 Lerner Drive, Blacklick, OH 43004.  
My email is julia.rose@osumc.edu or jrose9@une.edu 
If you have any questions or concerns, please contact me at (304) 559-7034. Thank you so much 
for your time and effort.  
 
Sincerely, 
 
 
 
Julia Rose, MSPAS, Principal Investigator 
PA-C at The Ohio State University Medical Center 
Doctoral Candidate University of New England 
 
